Search Results

Many pharmacology experiments produce beautifully clean assay curves. Potency estimates appear precise, maximal responses align neatly, and screening data generates clear rank orderings of compounds. The harder question is what those assay signals actually predict biologically. Drug discovery programs rarely fail because an assay produced poor data. They fail because the interpretation of that data did not translate to biology outside the assay system . Pharmacology exists precisely to bridge that gap. It creates conceptual scales that allow scientists to project observations from one experimental system into another. During a recent AMA discussion, several experienced scientists raised questions about assay scaling, pharmacokinetics, and discovery decision-making. Dr. Kenakin used those questions to explore how pharmacological reasoning turns experimental signals into actionable insight. In this session, you’ll gain: How pharmacology translates assay signals into biological predictions Why EC₅₀ values rarely capture the full pharmacological picture How binding kinetics and PK considerations influence discovery decisions Drug Discovery Pharmacology Principles in Action Drug discovery pharmacology principles revolve around one core idea: translation . Chemistry identifies molecules. Biology reveals targets. But pharmacology asks a different question: How will this molecule behave in a system we have not yet tested? That predictive step is essential because discovery scientists almost always operate inside partial models  of biology. Key realities pharmacologists face: Assays measure one slice of biology Disease physiology involves many interconnected systems Drug concentrations constantly rise and fall in vivo Pharmacology therefore constructs conceptual scales—linking ligand binding, receptor activation, and downstream signaling—to project how molecules behave beyond the assay. As Dr. Kenakin explains, pharmacology differs from other life sciences precisely because it builds quantitative frameworks that allow projection from one system to another.   The Assay Window Problem Every functional assay operates within a measurement window , and interpreting results requires understanding how responses scale within that window. Consider calcium flux assays: Teams often ask how to define fractional receptor activation, similar to how forskolin establishes maximal cAMP signaling. Practical strategies include: Using known controls (e.g., ATP or carbachol) to define maximal signal Normalizing agonist responses to a common reference window Accepting that maximal response may be estimated rather than exact In practice, the precise maximal signal matters less than many assume. When responses are scaled consistently, comparisons remain meaningful even if the absolute maximum is imperfect. As Dr. Kenakin notes, much of the interpretive power comes from the EC₅₀ component of the response , while small differences in maximal signal contribute relatively little to the overall interpretation. EC₅₀ Misconceptions Persist Few misunderstandings derail discovery programs faster than misinterpreting EC₅₀. Even experienced biologists sometimes treat EC₅₀ as if it reflects ligand affinity. In reality, it represents something very different: EC₅₀ is a system-dependent measure of functional response. It reflects: receptor density signaling efficiency assay sensitivity downstream amplification Not simply ligand binding. This distinction becomes especially important when comparing mutants, partial agonists, or signaling pathways. A ligand may show identical EC₅₀ values in two assays while engaging receptors through very different mechanisms. Understanding this distinction allows teams to: interpret pharmacological differences across systems normalize mutant receptor data avoid misleading potency comparisons Dr. Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes even when expression levels vary. Time Matters More Than Potency For decades, discovery teams prioritized potency above all else. The logic seemed obvious: Higher potency → lower dose → fewer side effects. But this assumption misses a crucial pharmacological reality: biological systems operate in time, not equilibrium. Drug concentrations constantly change as molecules: distribute through tissues bind and unbind receptors undergo metabolism and clearance This dynamic environment makes residence time —how long a ligand stays bound to its receptor—critically important. Two compounds with identical potency may behave very differently in vivo if one remains bound longer. Dr. Kenakin highlights that therapeutic efficacy depends on the period during which a drug is actively engaged with its target , not simply how strongly it binds at equilibrium. When PK Ends Programs Discovery teams often fall in love with molecules that show beautiful activity in vitro. But pharmacology introduces a sobering truth: A drug that cannot reach its target is not a drug. Pharmacokinetics—absorption, distribution, metabolism, and excretion—must therefore be addressed early. Common PK deal breakers include: poor solubility preventing absorption rapid clearance eliminating exposure sequestration in tissues or proteins One classic example occurs when compounds dissolve poorly, behaving essentially like inert particles within biological systems. Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo . The good news is that modern technologies—from delivery systems to alternative dosing routes—are dramatically expanding the options available to rescue promising scaffolds. Dr. Kenakin discusses how discovery teams balance enthusiasm for biological activity with the practical constraints of pharmacokinetics. Chemists Make The Drugs Drug discovery is fundamentally a team sport . Pharmacologists interpret biological data. But chemists transform that data into molecules capable of becoming medicines. Kenakin often recalls advice from Nobel laureate James Black: Chemists make the drugs. Your job as a pharmacologist is to guide them with solid data. This relationship defines productive discovery teams. Pharmacologists contribute: rigorous assay interpretation mechanistic insight into receptor signaling quantitative frameworks for decision making Chemists contribute: structural creativity scaffold optimization elimination of toxic chemical features Experienced chemists, for example, instinctively avoid known toxicophores —chemical groups associated with safety liabilities. When both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular design toward viable drug candidates. Failure Is the Real Curriculum Drug discovery carries a difficult truth: most programs fail. Even promising molecules collapse due to safety issues, pharmacokinetics, or unexpected biology. Yet failure is not a sign of weakness in discovery science. It is the mechanism by which progress occurs. Kenakin summarizes the mindset required with a quote attributed to Winston Churchill: Success is the ability to go from failure to failure without loss of enthusiasm. For scientists entering drug discovery, the lesson is simple: most hypotheses will be wrong most compounds will fail persistence is essential But the iterative process—assay, interpretation, redesign—ultimately produces the breakthroughs that transform medicine.Dr. Kenaking reveals how experienced pharmacologists turn repeated failures into increasingly powerful insights. Why Terry’s Corner Drug discovery pharmacology principles rarely appear in textbooks the way they are practiced in industry. Terry’s Corner  was created to close that gap. Subscribers gain access to: Weekly pharmacology lectures by Dr. Terry Kenakin Monthly live AMAs with real discovery questions A growing on-demand library of practical pharmacology insights The Corner is built for: pharmacologists refining core analytical tools discovery teams navigating development bottlenecks scientific leaders seeking clear pharmacological guidance GPCR innovation is accelerating rapidly. The scientists who strengthen their pharmacology foundations today will define tomorrow’s breakthroughs. Explore the full library and trailers ➤ https://www.ecosystem.drgpcr.com/terry-corner

The A2A adenosine receptor (A2AAR) is one of four adenosine receptor subtypes expressed in the human body (A1, A2A, A2B, and A3). It plays a key role in immune system downregulation, making it an attractive target for conditions in which immune reactivation is desired. A2AAR-targeted therapies have advanced to phase II clinical trials for various cancers, particularly in combination with other immune checkpoint inhibitors.1 In a shared effort to develop robust screening approaches  that can serve as practical alternatives to radioligand binding assays, Celtarys Research and PROMEGA combined their respective technologies to support GPCR drug discovery. A new NanoBRET® competitive binding assay 2  was developed in collaboration with Professor Kevin Pfleger’s laboratory (University of Western Australia), using a new Celtarys fluorescent ligand. Figure 1. Scheme of a competitive NanoBRET® assay. GPCRs are part of Celtarys’ expertise fields. Using a similar pharmacophore  to the one present in the A 2A AR probe CELT-300 , new fluorescent ligands adapted to the NanoBRET® technology were designed and synthesized. The Nanobret® 590 Dye  commercialized by PROMEGA was used as the fluorophore tag . The competitive assay design and optimization were performed in the University of Western Australia. GPCRs are part of Celtarys’ expertise fields. Using a similar pharmacophore  to the one present in the A 2A AR probe CELT-300 , new fluorescent ligands adapted to the NanoBRET® technology were designed and synthesized. The Nanobret® 590 Dye  commercialized by PROMEGA was used as the fluorophore tag . The competitive assay design and optimization were performed in the University of Western Australia. Combining Two Technologies Into One to Measure A2A Fluorescent Competitive Binding Bioluminescence resonance energy transfer  (BRET) serves as the basis for the NanoBRET® Target Engagement (TE) Technology. In this proximity-based approach, a NanoLuc®luciferase   genetically fused  to the target protein   transfers  bioluminescence to a fluorescent   tracer  binding to the target protein. In the competitive assay, A 2A AR ligands are set to compete with the probe , and the interactions  between the ligands and protein are quantified in real time  by measuring the probe’s emission in intact cells. To synthesize the probe, Celtarys has applied its proprietary conjugation technology . First the fluorescent ligand is properly functionalized to keep its activity intact. Then, the linker composition is optimized, by using different hinges and spacers . Afterwards, the fluorophore is attached and the final probes evaluated.  Celtarys’ technology significantly reduces the time it takes to obtain fluorescent tags and test varying linker structures and lengths, and it was used here to ensure optimal performance in NanoBRET® TE assays. Results The combination of both technologies, and the expertise of Prof. Pfleger’s group in developing assays, led to two new A 2A AR tracers (CELT-463 and CELT-464) , bearing the same pharmacophore and fluorophore, but with different linkers. They can be used to verify target engagement  and calculate ligand affinity  in a NanoBRET ®-based competitive binding assay .  Saturation binding experiments on NanoLuc®-tagged A2A receptors. First, saturation binding assays were performed . They are needed to identify the best concentrations for each tool. The curves obtained were consistent, and high specific binding  and optimal signal to noise rat io were observed. Figure 2 . Saturation Binding Experiment for CELT-463 (KD=33±4nM) and CELT-464 (KD=44±5nM) using HEK293FT cells transiently transfected with signal peptide nanoluc®-A2AAR expression vector.  Transfected cells were treated with increasing concentrations of CELT-463 or CELT-464 in the presence (non-specific binding) or absence (total binding) of SCH 442416. Specific binding was calculated by subtracting non-specific binding from total binding (mean±SEM, n=6). NanoBRET® competitive binding assays on A2AAR with CELT-463 and CELT-464 Using the previous data as reference, 50nM was chosen as the tracer concentration  for the assays, as it produces a sufficiently large window to perform the experiment. Increasing concentrations of the competitor compounds were added and the signal measured. As seen in figure 2, a heterogenous set of compounds  (agonists and antagonists, different structures) was measured using both CELT-463  and CELT-464 . Figure 3. Measurement of competitive ligand binding to A2AAR using tracers CELT-463 and CELT-464 in NanoBRET® assays for a set of reference compounds. Cells expressing signal peptide-nanoluc®-A2AAR were treated with 50nM CELT-463 or CELT-464 in the presence of increasing concentrations of various competitor compounds (mean±SEM, n=6). Selective or promiscuous, agonists or antagonists were for all 4 Adenosine Receptors were included in this set. the data obtained were compared with those reported in literature, which were obtained employing radioligand binding assays. Table 1. Set of reference compounds tested for assay validation, together with the reported and experimental binding data. PKI values were derived from pIC50 values using the Cheng-Prusoff equation. 3 The pK i values display a similar order  of affinity to the reported values , guaranteeing the NanoBRET® competitive binding assay on A 2A AR, meaning CELT-463  and CELT-464  are a valid alternative  to radioligand binding and other traditional methodologies. Conclusions This collaboration between PROMEGA, Celtarys Research, and the University of Western Australia led to the identification of two fluorescent ligands, CELT-463  and CELT-464 , optimized for NanoBRET®-based A2A fluorescent competitive binding affinity screening. Both are effective as NanoBRET® TE tracers, leading to similar results to those present in literature using traditional screening methods. As a proof of concept, the study shows that Celtarys’ chemistry can be translated into NanoBRET ® TE GPCR assays compatible with 384-well screening formats. For research teams, this provides a practical framework for integrating fluorescent ligand design with live-cell target engagement assays. The next step will be to determine how broadly this approach can be extended across GPCR families and how predictive these measurements are in downstream discovery workflows. Check the method to perform this assay and other case studies we have done on our website: https://www.celtarys.com/case-studies   References (1) Rodríguez-Pampín, I.; González-Pico, L.; Selas, A.; Andújar, A.; Prieto-Díaz, R.; Sotelo, E. Targeting the Adenosinergic Axis in Cancer Immunotherapy: Insights into A2A and A2B Receptors and Novel Clinical Combination Strategies. Pharmacological Reviews   2025 , 77  (6), 100092. https://doi.org/10.1016/j.pharmr.2025.100092 . (2) Stoddart, L. A.; Johnstone, E. K. M.; Wheal, A. J.; Goulding, J.; Robers, M. B.; Machleidt, T.; Wood, K. V.; Hill, S. J.; Pfleger, K. D. G. Application of BRET to Monitor Ligand Binding to GPCRs. Nature Methods   2015 , 12  (7), 661–663. https://doi.org/10.1038/nmeth.3398 .  (3) Todde, S.; Moresco, R. M.; Simonelli, P.; Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Varani, K.; Monopoli, A.; Matarrese, M.; Carpinelli, A.; Magni, F.; Kienle, M. G.; Fazio, F. Design, Radiosynthesis, and Biodistribution of a New Potent and Selective Ligand for in Vivo Imaging of the Adenosine A2A Receptor System Using Positron Emission Tomography. J. Med. Chem. 2000, 43 (23), 4359–4362. https://doi.org/10.1021/jm0009843 . (4) Jacobson, K. A.; Gao, Z.; Matricon, P.; Eddy, M. T.; Carlsson, J. Adenosine A2A Receptor Antagonists: From Caffeine to Selective Non‐xanthines. British J Pharmacology 2022, 179 (14), 3496–3511. https://doi.org/10.1111/bph.15103 . (5) Borrmann, T.; Hinz, S.; Bertarelli, D. C. G.; Li, W.; Florin, N. C.; Scheiff, A. B.; Müller, C. E. 1-Alkyl-8-(Piperazine-1-Sulfonyl)Phenylxanthines: Development and Characterization of Adenosine A2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity. J. Med. Chem. 2009, 52 (13), 3994–4006. https://doi.org/10.1021/jm900413e . (6) Klotz, K.-N. Adenosine Receptors and Their Ligands. Naunyn-Schmied. Arch. Pharmacol. 2000, 362, 382-391. https://doi.org/10.1007/s002100000315 (7) Jacobson, K. A. Introduction to Adenosine Receptors as Therapeutic Targets. In Adenosine Receptors in Health and Disease; Wilson, C. N., Mustafa, S. J., Eds.; Handbook of Experimental Pharmacology; Springer Berlin Heidelberg: Berlin, Heidelberg, 2009; Vol. 193, pp 1–24. https://doi.org/10.1007/978-3-540-89615-9_1 . (8) Yung-Chi, C.; Prusoff, W. H. Relationship between the Inhibition Constant (KI) and the Concentration of Inhibitor Which Causes 50 per Cent Inhibition (I50) of an Enzymatic Reaction. Biochemical Pharmacology   1973 , 22  (23), 3099–3108. https://doi.org/10.1016/0006-2952(73)90196-2 .

Dr. GPCR is proud to partner with the 5th Annual GPCRs-Targeted Drug Discovery Summit.  This post is your one-stop hub — agenda highlights, who's attending, our exclusive discount code, and speaker interviews as they go live. Why the GPCR Drug Discovery Field Is Converging in Boston The GPCR field is in a genuinely exciting moment. Not hype — momentum. The human genome encodes ~800 GPCRs, yet only around 15% are currently targeted by approved drugs — leaving an enormous and largely untapped therapeutic opportunity. New structural tools, AI-driven design pipelines, and a growing number of programs moving into the clinic are redefining what's possible across modalities and indications. Pharma interest is high, as reflected in major deals across the space. The 5th Annual GPCRs-Targeted Drug Discovery Summit is the industry-led meeting dedicated entirely to GPCR drug discovery — across small molecules, peptides, and antibodies, and across indications. This year's program reflects where science is actually heading. Dr. GPCR founder Dr. Yamina Berchiche will be there — if you're attending, reach out to connect. Who's at the GPCR-Targeted Drug Discovery Summit 2026 The meeting brings together 80+ senior leaders from biotech and pharma to advance GPCR programmes from discovery through translation — experts in GPCR biology, structural biology, computational design, pharmacology, and translational strategy. Companies already confirmed to attend include: Abalone Bio  ·  AbbVie  ·  Biagon  ·  Biolexis Therapeutics  ·  Confo Therapeutics  ·  Eli Lilly  ·  GSK  ·  Nabla Bio  ·  Northeastern University  ·  Nxera Pharma  ·  OMass Therapeutics  ·  Superluminal Medicines  ·  Tectonic Therapeutics  ·  and many more. GPCR Drug Discovery Agenda Highlights: What's New in 2026 This year's summit runs across three days — an AI & ML Focus Day on April 28, followed by two conference days — and the program spans the full breadth of the field. Biased Signaling, Endosomal Pathways & GPCR Signaling Complexity How do we disentangle intrinsic, system, and kinetic bias in a way that actually predicts clinical outcomes? Sessions from InterAx Biotech, Northeastern University, and Function Therapeutics dig into this — moving beyond static potency and efficacy to mechanistic signatures that guide drug design. A panel discussion will tackle best practices for measuring GPCR signaling bias in vitro and what that means for in vivo and clinical translation. AI & ML in GPCR Drug Discovery A dedicated focus day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly. These aren't primers on AI — they're teams presenting real workflows and real data, covering generative antibody design, dynamic conformational modeling, federated computing platforms, and predictive simulations that shorten discovery timelines. Antibodies, Cyclic Peptides & Allosteric Modulators Nine or more presentations on non-small molecule approaches — including agonistic antibodies, GPCR-directed ADCs, orally available cyclic peptides, and allosteric probes for Class B GPCRs. Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies, and Abilita Therapeutics. Translational Stories & Clinical Data OMass Therapeutics on long-residence MC2R antagonists. Tectonic Therapeutics on engineering a long-acting relaxin for pulmonary hypertension. Kainova Therapeutics presenting Phase 1 outcomes for their EP4 receptor antagonist in solid tumors. Alphamol on Phase 1 results from an orphan GPCR program pursued against industry skepticism. 🎥 Speaker Spotlight: GPCR Drug Discovery Experts to Watch (coming soon) In the run-up to the summit, we're speaking with some of the researchers presenting at the meeting. We'll be adding interviews here as they go live — check back for updates. Register for the GPCR Drug Discovery Summit — Exclusive DrGPCR Discount Use the exclusive DrGPCR discount code DRGPCR10 at checkout for 10% off registration. Early bird pricing also runs through March 6 , saving up to $600 off the door price — so don't wait.   🔗  Register here   🔗  Explore the full event guide   🔗  Contact the event team for your discount The 5th Annual GPCRs-Targeted Drug Discovery Summit takes place April 28–30, 2026 at The Colonnade, 120 Huntington Avenue, Boston, MA.

Selectivity is one of the most overused—and misunderstood—terms in drug discovery. A compound shows no response in one assay, and we call it “selective.” Another produces a larger shift in EC₅₀ in one system than another, and we assume we’ve found therapeutic separation. But as Dr. Kenakin demonstrates in this session of Terry’s Corner, what we often measure is not receptor selectivity. It’s a partnership between ligand efficacy and the sensitivity of the cellular system used to detect it. In this session, you’ll gain: A framework for cancelling cell effects to isolate true receptor selectivity Practical methods for calculating system-independent selectivity Clear distinction between receptor selectivity and signaling bias Quantifying Receptor Selectivity Requires Canceling the Cell In early discovery, comparing EC₅₀ values across compounds is a common first-pass strategy for ranking potency. But raw potency differences are not pure reflections of affinity or efficacy. They also encode: Receptor expression levels Coupling efficiency Signal amplification Assay sensitivity Observed agonism is never “just the ligand.” It is always ligand × system. In the full lecture, Dr. Kenakin reveals how two compounds tested in different systems can appear to differ by thousands-fold in selectivity—until the system contribution is mathematically cancelled. What remains may be a much smaller, but far more meaningful, difference. True receptor selectivity must transcend the cell line. Canceling the Cell If observed potency reflects both drug properties and system sensitivity, then system effects must be neutralized. The strategy is conceptually simple: Measure full concentration–response curves Calculate relative potencies within each system Perform a ratio-of-ratios comparison By comparing the relative potency of two agonists across two receptor systems—and then comparing those ratios to each other—system-dependent factors cancel out. What remains reflects differences in: Affinity Efficacy And importantly, this value becomes portable. It should hold regardless of receptor density or assay format. This is not just mathematical elegance. It is strategic clarity. It prevents discovery teams from advancing compounds based on artifacts of expression systems rather than intrinsic pharmacology. Why Full Curves Matter Selectivity measurements require full concentration–response curves. Not single concentrations. Not partial windows. Not truncated data. Why? Because the absence of observed agonism does not prove absence of efficacy . A low-efficacy agonist tested in a low-sensitivity system may show no visible response—even at concentrations where 50% receptor occupancy occurs. Move that same ligand into a more sensitive assay, and a curve appears. Dr. Kenakin uses a lever analogy where: Efficacy is the weight applied. System sensitivity determines whether the lever moves enough to be seen. If the assay threshold is too high, real pharmacology becomes invisible. This has direct implications: A “non-selective” compound may simply be under-detected. A “silent” ligand may be system-limited. A development decision may hinge on assay sensitivity rather than molecular behavior. Without full curves, you cannot separate drug properties from detection limitations. Comparing Full and Partial Agonists Discovery programs rarely enjoy the simplicity of comparing two full agonists. More often, one ligand is partial. Now EC₅₀ values alone are insufficient. Maximal response differs. Potency scales distort. Dr. Kenakin outlines a practical solution: use a potency metric that incorporates both efficacy and EC₅₀ (log maximal response divided by EC₅₀). This approach: Corrects distortions introduced by differing maximal responses Allows comparison across full and partial agonists Preserves system independence When handled correctly, partial agonists can be quantified on equal footing with full agonists—without biasing interpretation. Confidence, Not Just Ratios Selectivity is not just a number. It is an estimate with uncertainty. Delta–delta comparisons can be repeated, generating: Standard errors 95% confidence intervals And this is where interpretation sharpens. If confidence intervals include zero, selectivity is not statistically significant. If they exclude zero, the separation is real. In the full lecture, you will learn how this approach removes subjectivity from interpretation. No more “it looks selective.” Statistics decide. For teams under pressure to nominate leads, this discipline matters. It prevents overinterpretation of noise as biology. Receptor Selectivity vs Signaling Bias Here is where the conversation becomes more nuanced. Receptor selectivity involves concentration separation. A compound binds receptor A and produces a response at one range of concentrations. Only at much higher concentrations does receptor B become engaged. Bias is different. Bias occurs simultaneously with receptor binding. When the ligand engages the receptor, multiple signaling pathways initiate: G protein activation β-arrestin recruitment Calcium signaling Other downstream cascades But they do not activate with equal intensity . Bias reflects differential pathway amplification at the same receptor—not concentration separation across receptors. This distinction is critical: Receptor selectivity separates by concentration window. Bias separates by signaling strength. You will learn how the same ratio-of-ratios framework can be applied within a receptor to quantify pathway bias. But caution is required. If pathway-specific readouts are used to define receptor selectivity, then both agonists must be evaluated using the same pathway. Otherwise, bias contaminates the selectivity calculation. Whole-Cell Responses: A Historical Complication Historically, pharmacology relied on whole-cell or tissue responses. These are integrated outputs. They blend multiple pathways into a single functional readout. This has advantages: Physiological relevance Functional integration But it obscures pathway-specific behavior. Modern assays allow isolation of discrete signaling nodes. This precision is powerful—but it introduces complexity. Each pathway can produce a different apparent selectivity profile. In the end, what matters therapeutically is the integrated response. But during discovery, pathway dissection can clarify mechanism and reveal hidden liabilities. The key is consistency: define which pathway defines “selectivity,” and stay faithful to it. Strategic Implications for Drug Hunters Quantifying receptor selectivity correctly does more than refine pharmacological metrics. It changes decisions. It prevents false negatives caused by insensitive assays. It avoids overestimating subtype separation. It clarifies whether differentiation is receptor-based or pathway-based. It creates transportable, system-independent numbers. In a world of increasingly complex GPCR modulation, these distinctions are not academic. They define risk. Compounds fail when assumptions about selectivity prove wrong in vivo. Often, the error began at the assay stage. Quantification—done correctly—protects pipelines. Why Terry’s Corner Terry’s Pharmacology Corner delivers weekly lectures from Dr. Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity fast. It is designed for: Pharmacologists sharpening foundational tools Discovery teams solving assay bottlenecks Leaders making mechanism-driven portfolio decisions GPCR innovation is accelerating. Those who master system-independent thinking today will define tomorrow’s breakthroughs. 40 years of expertise at your fingertips: Explore the full library and trailers ➤ https://www.ecosystem.drgpcr.com/terry-corner

GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry. They play a role in various pathologies, including neurological, oncological, degenerative, metabolic, and immunological conditions. Approximately one-third of the drugs currently in clinical use are GPCR ligands. The Impact of Twist Bioscience Twist Bioscience serves life science researchers who are dedicated to improving the world. These scientists come from diverse fields such as medicine, agriculture, industrial chemicals, and data storage. They utilize synthetic genes, oligo pools, and NGS target enrichment to enhance lives and promote sustainability. Twist Bioscience's technology addresses inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. However, researchers faced a challenge with the target C5aR , as they lacked the appropriate tools to study it in depth. The C5a anaphylatoxin chemotactic receptor 1, also known as CD88, is part of the rhodopsin family of GPCRs . Interest in this receptor has surged recently due to its involvement in several inflammatory pathologies , including asthma, arthritis, sepsis, and more recently, Alzheimer's disease and cancer. Its activation triggers immunological responses , such as chemotaxis, activation, and inflammatory signaling . Understanding the molecular binding mechanism behind C5a and C5aR interaction is crucial for developing novel immunological therapeutics. To accelerate ligand development for C5aR, new tools must be developed . Fluorescence-based assays, such as flow cytometry or fluorescence polarization, can be used for medium or high-throughput screening. However, there is a notable lack of fluorescent probes available in the market for this receptor. Celtarys Conjugation Technology Figure 2. General structure of ligands architecture obtained by Celtarys Technology. At Celtarys , we employ various conjugation techniques , including our proprietary semi-combinatorial approach . This method has been validated for developing fluorescent ligands with optimal properties for different assays and has been applied to several GPCRs. A bibliographic search accompanied by in silico modelling is essential to determine the appropriate pharmacophore . A deep understanding of the structure-activity relationship helps identify a suitable location for the linker. The final pharmacophore is derived from a set of at least 3-5 different chemical scaffolds. The pharmacophore is then functionalized in the best position for introducing a linker. Various spacers and hinges are utilized at this stage, and the biological evaluation of these compounds enables us to identify the most effective linker for the target. The final step involves introducing fluorophores suitable for the desired assays. The activity of the final molecules is measured in binding or functional assays, allowing us to select the best candidate. Figure 3. Development process of fluorescent probes using Celtarys technology and its stages. C5aR Fluorescent Ligand Development Initially, a detailed analysis of the published ligands for C5aR is performed. For competition-based screening, antagonists are preferred as they exhibit the same affinity for both active and inactive receptor conformations and do not trigger internalization . Three scaffolds were selected ( P1, P2, and P3 ), considering their activity range, structure-activity relationship, available information, chemical scaffold, and synthetic accessibility. The C5aR has been crystallized with the cyclopeptidic antagonist PMX53 . This provides valuable information regarding the potential fitting of our three pharmacophores through computational methods , along with the SAR studies conducted after the chemical functionalization of the scaffolds. During Stage 1 of the project, four promising functionalized structures of P1 demonstrated a K* B** of less than 100nM* in a Calcium flux assay (Ready-to-AssayTM, C5aR Anaphylotoxin Receptor Frozen Cells from Eurofins). These four candidates were selected for the next step, which involved the introduction of linkers (Table 1, Stage 2). Table 1. Biological activity of the most representative compounds synthesized in C5aR fluorescent ligand development project. * In addition to the W-54011, the unmodified pharmacophore 1 was used as internal control for further assay validation. Using our proprietary technology, several linkers were assembled , combining the suitable functionalized pharmacophores with different hinges and spacers. The linker structures are filtered based on the desired physicochemical properties. An initial set of compounds based on functionalized P1 combined with different linkers was synthesized. However, none of these compounds exhibited a K* B** of less than 100nM* , unlike the functionalized P1 scaffold. Consequently, different combinations of P1+linkers and a P3 functionalized scaffold + linker were also tested, with the P3+linker (MFLV50) emerging as the highlight (Table 1, blue). The most promising scaffolds were labeled with a red-emitting fluorophore, Cy5 . While the activity was not optimal, there was a discrepancy between biological results and expected activity based on the docking studies using the crystal structure. For instance, MFLV18 (Table 1, blue) was anticipated to establish an intramolecular hydrogen bond, simulating the fold present in PMX53. Neither fluorescent P1 nor P3 showed good activity in calcium functional assays. The best compound identified was CELT-58 , which was obtained by combining MFLV18 with Cy5, showing a K* B** of 5788nM* (Table 1, red). Further assays were conducted in a more extensive manner. Seven compounds based on P1 and P3 were tested by Twist Bioscience. A Flow Cytometry C5aR binding assay was performed in both C5aR-HEK (Multispan) and C5aR-Chem1 (DiscoverX) transfected cell lines, along with the cAMP HunterTM eXpress C5aR CHO-K1 GPCR Assay. cAMP Functional Assays Only P1 (MFLV59) and the P3+linker conjugates MFLV50 and MFLV66 , as well as the fluorescent compound CELT-68 (based on P3) , demonstrated activity in cAMP assays (Figure 4, Table 1). Figure 4. cAMP functional assays performed on representative precursors and final fluorescent probes. Flow Cytometry Binding Assays The best saturation curves of the seven fluorescent ligands were obtained in C5aR Chem-1 transfected cells, indicating high specific binding (Figure 5). Figure 5. Specific binding of the most promising fluorescent antagonists in Chem 1 cell lines. The signal in C5aR transfected Chem-1 is compared with the untransfected parent cell line to study fluorescent probe specific binding. Both CELT-58 and SG65 exhibited strong binding properties across different cell lines. Figure 6. EC50 affinities obtained by flow cytometry saturation binding experiments in C5aR transfected Chem-1 cell line. For those curves which did not reach plateau the EC50 was not reported since the data may not be accurate.* Subsequently, CELT-58 and CELT-68 were utilized in competition assays at EC50 concentration , against the endogenous peptidic ligand C5a (Figure 7). CELT-58 achieved a remarkable EC* 50** of 30.38nM* , while CELT-68 demonstrated high activity in cAMP . Figure 7. C5aR competition binding of CELT-58 and CELT-68 with the endogenous ligand C5a by flow cytometry. Discussion The efficiency, versatility, and convergence of our proprietary conjugation technology enabled the design and synthesis of numerous exploratory compounds in a short time. Over 50 different molecules were synthesized following the established three-stage process, leading to two optimal fluorescent tools for C5aR screening . Good biological activity was observed in the Calcium Flux Assay for the functionalized ligands based on P1 (low nanomolar range). However, this activity diminished in Stage 2 after the linkers were attached. Consequently, Stage 3 labeling was performed with moderate activity conjugates . Seven fluorescent ligands with P1 and P3 pharmacophores were characterized biologically in greater depth. CELT-58 and CELT-68 were identified as valuable tools for conducting competition binding assays by flow cytometry . These results underscore how the type of assay can yield different results and how critical information may be lost by not conducting sufficient studies. Conclusions By applying our proprietary technology, we have designed and synthesized two optimal fluorescent probes for C5aR : CELT-58 and CELT-68 . Both ligands exhibit high specific binding to C5aR in saturation binding assays (Figure 5) and demonstrate good competition with the endogenous ligand C5a by flow cytometry (Figure 7). Both are orthosteric ligands with antagonistic activity in Calcium and cAMP assays (Table 1). These two fluorescent probes have proven to be optimal tools to perform fluorescence-based assays to unlock the therapeutic potential of this important receptor. References (1) Hauser, A. S.; Attwood, M. M.; Rask-Andersen, M.; Schiöth, H. B.; Gloriam, D. E. Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nature Reviews Drug Discovery 2017 , 16 (12), 829–842. https://doi.org/10.1038/nrd.2017.178 . (2) Dumitru, A. C.; Deepak, R. N. V. K.; Liu, H.; Koehler, M.; Zhang, C.; Fan, H.; Alsteens, D. Submolecular Probing of the Complement C5a Receptor–Ligand Binding Reveals a Cooperative Two-Site Binding Mechanism. Commun Biol 2020 , 3 (1), 786. https://doi.org/10.1038/s42003-020-01518-8 . (3) Monk, P. N.; Scola, A.; Madala, P.; Fairlie, D. P. Function, Structure and Therapeutic Potential of Complement C5a Receptors. British J Pharmacology 2007 , 152 (4), 429–448. https://doi.org/10.1038/sj.bjp.0707332 . (4) Barbazán, J.; Majellaro, M.; Brea, J. M.; Sotelo, E.; Abal, M. Identification of A2BAR as a Potential Target in Colorectal Cancer Using Novel Fluorescent GPCR Ligands. Biomedicine & Pharmacotherapy 2022 , 153 , 113408. https://doi.org/10.1016/j.biopha.2022.113408 . (5) Raïch, I.; Rivas-Santisteban, R.; Lillo, A.; Lillo, J.; Reyes-Resina, I.; Nadal, X.; Ferreiro-Vera, C.; De Medina, V. S.; Majellaro, M.; Sotelo, E.; Navarro, G.; Franco, R. Similarities and Differences upon Binding of Naturally Occurring Δ9-Tetrahydrocannabinol-Derivatives to Cannabinoid CB1 and CB2 Receptors. Pharmacological Research 2021 , 174 , 105970. https://doi.org/10.1016/j.phrs.2021.105970 . (6) Miranda-Pastoriza, D.; Bernárdez, R.; Azuaje, J.; Prieto-Díaz, R.; Majellaro, M.; Tamhankar, A. V.; Koenekoop, L.; González, A.; Gioé-Gallo, C.; Mallo-Abreu, A.; Brea, J.; Loza, M. I.; García-Rey, A.; García-Mera, X.; Gutiérrez-de-Terán, H.; Sotelo, E. Exploring Non-Orthosteric Interactions with a Series of Potent and Selective A3 Antagonists. ACS Med. Chem. Lett. 2022 , 13 (2), 243–249. https://doi.org/10.1021/acsmedchemlett.1c00598 . (7) Liu, H.; Kim, H. R.; Deepak, R. N. V. K.; Wang, L.; Chung, K. Y.; Fan, H.; Wei, Z.; Zhang, C. Orthosteric and Allosteric Action of the C5a Receptor Antagonists. Nature Structural & Molecular Biology 2018 , 25 (6), 472–481. https://doi.org/10.1038/s41594-018-0067-z .

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. New opportunities appear constantly. That is not a flaw. It is the nature of scientific possibility. 👉 The problem begins when ambition grows faster than structure. What feels like momentum can quietly become dilution. More programs. Broader roadmaps. Increasing complexity. And slowly, strategic focus weakens . This is the hidden cost of ambition in biotech leadership. Not failure. Not poor science. But loss of disciplined prioritization . The real challenge for biotech leaders is simple and demanding at the same time: 👉 How do you stay ambitious without compromising strategic control and biotech fundraising credibility? In biotech leadership, ambition opens opportunity, but strategic discipline turns scientific potential into sustainable progress and stronger biotech fundraising credibility. Why Ambition Naturally Expands in Biotech Companies 👉 Ambition in biotech is data-driven. One validated mechanism suggests multiple indications. A strong preclinical signal opens adjacent therapeutic areas. A platform technology reveals additional applications. With every experiment, the opportunity surface expands . Saying no to those opportunities feels counterintuitive. If the science supports it, why not pursue it? This is where the structural tension begins. 👉 Scientific optionality grows faster than strategic capacity.   The leadership team now manages not one path, but several plausible futures. Each looks promising. Each feels defensible. Each appears aligned with long-term value creation. But optionality is not the same as priority. Every additional program introduces complexity. It consumes leadership attention. It reallocates capital. It reshapes milestones. And slowly, without dramatic failure, focus begins to fragment . The company does not become weaker. It becomes broader. And broader often means less sharp. 👉 For biotech leaders, this is the critical realization: ambition expands naturally, but strategic focus must be deliberately engineered. ✅ Without that engineering, growth in opportunity turns into growth in friction. And friction directly influences execution clarity and biotech fundraising confidence. How Strategic Friction Quietly Slows Execution 👉 Strategic friction rarely announces itself loudly. There is no dramatic collapse. No visible crisis. Instead, momentum becomes inconsistent. Teams feel busy, but outcomes feel less decisive. Leadership conversations take longer. Milestones shift slightly. Roadmaps grow more complex. None of this looks alarming in isolation. 👉 The real issue is accumulation. When ambition expands without clear sequencing, the organization begins to operate in parallel across too many priorities. And parallelism without hierarchy creates dilution. 👉 Strategic friction typically shows up in four ways: Too many active programs are competing for the same capital and talent Milestones that lack a clear primary value inflection point Leadership attention is fragmented across exploratory initiatives A narrative that becomes harder to explain in one clear sentence Each of these signals the same underlying problem: 👉 The company has not explicitly chosen what matters most right now. Execution slows not because the team is weak, but because energy disperses. Capital efficiency decreases not because spending increases, but because allocation becomes less sharp. And this is where biotech fundraising begins to feel harder than it should. Investors respond to clarity. They respond to a disciplined path toward a defined milestone. When strategic friction increases, confidence decreases. Not because the science is flawed, but because the trajectory is less precise. 👉 The important distinction is this: ambition creates opportunity, but lack of prioritization creates noise. ✅ The next step is structuring it. Think. Decide. Lead. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech fundraising outcomes tomorrow. What Strategic Discipline Actually Looks Like in Practice Strategic discipline does not mean shrinking your vision. It means structuring how that vision unfolds over time . 👉 The strongest biotech leaders understand that ambition must be sequenced. Not all programs are equal at every stage. Not all indications create the same validation effect. Not every opportunity strengthens the company right now. Disciplined ambition starts with a simple shift in thinking. Instead of asking, “What could we pursue?” the better question becomes, “What must we prove first?” This reframes strategy around value inflection points. It forces clarity about which milestone unlocks the next layer of credibility, capital, and optionality. ✅ It aligns science, capital allocation, and communication into one coherent direction. Strategic discipline also requires explicit trade-off awareness. Every new initiative delays something else. Every expansion consumes attention. When leaders make those trade-offs visible and deliberate , the organization gains focus without losing ambition. Importantly, discipline does not eliminate optionality. It preserves it. By sequencing execution and concentrating resources, the company increases the probability that future expansion will be funded, supported, and believable. ✅ This is where biotech fundraising becomes directly connected to strategic structure. Investors fund companies that demonstrate controlled expansion. They look for ambition that is ambitious but engineered. ✅ In other words, strategic discipline does not limit growth. It protects it. The CEO Decision Filters That Protect Both Focus and Biotech Fundraising 👉 Strategic discipline becomes real at the decision level. Not in strategy decks. Not in vision statements. But in what the CEO chooses to prioritize this quarter. When ambition expands, leaders need explicit filters. Without them, every opportunity feels equally important. 👉 The following decision criteria help protect strategic focus while strengthening biotech fundraising credibility: 1️⃣ Does this initiative accelerate our primary value inflection point? If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention. 2️⃣ What are we implicitly delaying by saying yes to this? Every expansion consumes capital, time, and leadership bandwidth. Trade-offs must be visible. 3️⃣ Will this sharpen or blur our core company narrative? If the story becomes harder to explain in one clear sentence, strategic clarity is weakening. 4️⃣ Does this strengthen our capital efficiency or increase fragmentation? Investors evaluate not only ambition but allocation discipline. 5️⃣ Are we expanding because it is strategic, or because it is intellectually exciting? Scientific curiosity is powerful. But companies scale on prioritized execution. ✅ These filters do not restrict ambition. They structure it. When leaders consistently apply disciplined decision criteria, the organization gains confidence. Teams understand what matters most. Capital aligns with milestones. The external narrative becomes coherent. ✅ And over time, biotech fundraising becomes less about persuasion and more about demonstrated strategic control. Ambition attracts attention. Discipline earns trust. Strategic Takeaway Ambition will always be part of biotech leadership. It fuels platforms, pipelines, and long-term vision. 👉 But ambition without structure creates drift . 👉 The leaders who scale successfully understand one core principle: focus is not a constraint; it is a strategic multiplier . When priorities are sequenced, capital is aligned with clear milestones, and trade-offs are made explicit, complexity turns into momentum. This is where execution strengthens. This is where credibility increases. This is where biotech fundraising becomes more predictable. ✅ In the end, the advantage is simple but rare: Think big. Execute narrow. Expand deliberately. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology AMA of 2026  at Terry’s Corner will take place on: Thursday, February 26 at 1 PM EST Dr. Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery challenges — driven by questions from the community. These sessions focus on real scientific uncertainty, not rehearsed presentations. Terry’s Corner Expands to YouTube Terry’s Corner is now on YouTube. Three videos are already live, and the channel will expand regularly. The objective is straightforward: Make mechanistic pharmacology easier to access, revisit, and apply across research teams. Short conceptual breakdowns Focused receptor theory discussions Clear explanations reinforcing disciplined interpretation As the archive grows, it becomes a searchable extension of Terry’s teaching — designed for repeated exposure rather than one-time viewing. Subscribe to stay current as new videos are released: ▶️ https://www.youtube.com/@TerryPharmacologyCorner New White Paper on GPCR Biased Signaling Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina School of Medicine, has authored a new white paper in collaboration with Eurofins DiscoverX: Assess GPCR Biased Signaling of Agonists Using Functional Cell-Based Assays The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic profiles Application of quantitative tools such as transduction coefficients (log(τ/KA) or log(max/EC50)) Systematic comparison of biased agonists using modern functional assays For scientists working in GPCR programs, this connects functional assay data directly to translational decision-making — moving beyond descriptive bias claims toward quantitative rigor. Access the white paper here Why Terry’s Pharmacology Corner Mechanistic understanding evolves. What appears settled under one experimental condition may require refinement under another. What seems definitive during early screening can shift as assay systems, receptor expression levels, or kinetics change. Pharmacology does not drift because data are missing. It drifts when interpretation becomes casual. Terry’s Pharmacology Corner provides a structured environment to maintain interpretive discipline: Weekly advanced pharmacology lectures Monthly live AMAs for real-time scientific discussion A continually expanding on-demand archive Sustained exposure to quantitative receptor theory and mechanistic reasoning The value lies not in a single explanation, but in preserving rigor as programs mature. Forty years of pharmacological expertise — organized into a year-round framework for serious GPCR scientists. Stay in the Know If you want updates on future AMAs, new YouTube releases, white papers, and ongoing pharmacology insights, join Terry Kenakin’s Brief . Concise. Focused. Mechanistic. 👉 Sign up here Continue the Work Live sessions are one layer. Sustained exposure is where judgment sharpens. If you want structured, year-round access to Terry’s full library — including advanced lectures, archived AMAs, and quantitative pharmacology deep dives: 👉 Access Terry’s Corner Free for 7 Days Strengthen Your Mechanistic Thinking

👉 In early-stage biotech, activity often feels like strategy. The platform is advancing, multiple indications are progressing, a grant application is underway, and early partnership conversations are taking shape. At the same time, the team is preparing for biotech fundraising. On the surface, this looks like a strength. There is movement across the board. Each initiative has logic behind it. Each program appears to increase optionality and reduce risk. 👉 This is where strategic overload begins. Strategy is defined by the clarity of the commitment you make. When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. Decision-making slows. The narrative becomes broader but less decisive. The organization feels busy, yet something subtle shifts. No single milestone clearly dominates. No single value inflection point anchors the story. Internally, this feels manageable. Externally, especially in biotech fundraising, it signals hesitation. 👉 The real cost of strategic overload in biotech is not complexity. It is a diluted commitment. And diluted commitment quietly shapes investor perception long before the first pitch meeting ever takes place. Real strategy begins when ambition meets discipline and leadership chooses where to concentrate energy before biotech fundraising. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions. A second indication looks promising. A platform application opens a larger market. A grant opportunity aligns with ongoing research. A potential partner shows interest. Each move can be justified. Each initiative appears to strengthen the company ahead of biotech fundraising. Individually, these choices make sense. Collectively, they create diffusion. ✅ Strategy is the concentration of commitment. In early-stage biotech, resources are finite. Capital is limited. Leadership attention is stretched. When multiple programs advance at the same time, trade-offs become implicit instead of explicit. Nothing is formally deprioritized. Nothing is clearly paused. Everything remains alive. This creates a subtle but powerful shift. Milestones no longer build toward a single dominant value inflection point. Instead, they scatter across parallel tracks. The organization becomes efficient at managing activity, but less effective at signaling conviction. 👉 Conviction requires exclusion. Without exclusion, the company appears broad but not decisive. The scientific ambition may be impressive, yet the strategic narrative loses sharpness. Internally, this feels like diversification. Externally, especially in biotech fundraising, it feels like hesitation. The danger is not visible chaos. It is strategic ambiguity. 👉 And ambiguity is expensive long before it shows up in a term sheet. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation of science. It is an evaluation of focus. Investors are not just asking whether the data is strong. They are assessing whether the company knows exactly where it is going and why. When strategic overload sets in, that clarity begins to erode. The problem is not that there are multiple programs. The problem is that no single program clearly dominates the capital narrative. 👉 Biotech fundraising rewards concentrated signal. Strategic overload produces a diluted signal. When too many priorities move in parallel, several things happen at onc e: 👉 The primary value inflection point becomes unclear 👉 Capital allocation appears fragmented 👉 The development timeline looks crowded rather than sequenced 👉 The story shifts from decisive execution to optional exploration 👉 The perceived execution risk increases None of these issues is dramatic on its own. Together, they create hesitation. From the outside, investors start to ask subtle questions. What is the real bet? Which milestone truly changes the company’s valuation? If capital is deployed today, where does it concentrate and why? If the answers are layered across multiple initiatives, confidence weakens. 👉 Biotech fundraising momentum depends on a visible throughline. That throughline is not a slide in a deck. It is the structural alignment between capital, milestones, and narrative. When resources are spread across too many initiatives, demonstrating alignment becomes harder. 👉 Strategic overload does not make a company look incompetent. It makes it look uncertain. And uncertainty, even when the science is strong, slows biotech fundraising more than most founders expect. Commitment over complexity. Strategic focus strengthens biotech fundraising long before investor conversations begin. Why Founders Rationalize Strategic Overload 👉 Strategic overload rarely feels like a mistake. It feels responsible. Founders in biotech operate under real pressure. Scientific opportunity is rarely linear. Platform technology invites expansion. Early data can point in multiple promising directions. At the same time, boards expect growth, grants require alignment, and potential partners introduce new possibilities. Saying yes often feels safer than saying no. Pursuing multiple paths creates the perception of diversification. If one program slows, another might accelerate. If one indication underperforms, another could generate traction. In the short term, this approach appears to reduce risk and strengthen the story ahead of biotech fundraising. 👉 But diversification at the strategy level is not the same as diversification in a portfolio. A startup is not a fund. It does not have unlimited capital, parallel leadership teams, or independent risk pools. Every additional initiative competes for the same executive attention, the same scientific bandwidth, and the same capital base. What begins as intelligent expansion gradually becomes structural strain. Founders often justify this strain through ambition. The science supports it. The data is promising. The market opportunity is real. Letting go of a program can feel like abandoning potential value. Yet the hardest strategic decisions are rarely about starting something new. They are about choosing what not to pursue. 👉 Strategic discipline requires visible trade-offs. Without explicit trade-offs, priorities accumulate. And when priorities accumulate, clarity declines. That decline may not disrupt daily operations, but it quietly weakens positioning long before biotech fundraising conversations begin in earnest. 👉 Strategic overload persists not because leaders lack intelligence, but because focus demands constraint. And constraint feels uncomfortable in an environment built on discovery. Rebuilding Strategic Discipline Before the Next Biotech Fundraising Cycle 👉 Strategic overload is not solved by better storytelling. It is solved by structural decisions. By the time biotech fundraising begins, investors are not only evaluating data. They are evaluating the architecture of your strategy. They want to see that capital will accelerate a clear thesis, not sustain a collection of parallel experiments. 👉 Strategic discipline must be visible in how the company allocates attention, capital, and sequencing. Before the next biotech fundraising cycle, leadership teams should pressure test their structure with uncomfortable clarity. 1️⃣ Identify the single dominant value inflection point. Which milestone most meaningfully changes the company's valuation? If it succeeds, does it materially strengthen your negotiating position? 2️⃣ Define the primary capital concentration zone. Where will the majority of new capital be deployed, and why? If capital appears evenly distributed, focus is likely diluted. 3️⃣ Clarify the sequencing logic. Are programs advancing because they are strategically ordered, or because they were never explicitly deprioritized? 4️⃣ Articulate the explicit trade-offs. What did you decide not to pursue to strengthen the main thesis? If nothing is clearly paused, the strategy is likely overloaded. 5️⃣ Stress test the narrative under investor scrutiny. Can the entire strategy be explained through one coherent throughline, or does it require layered justifications for multiple parallel bets? These questions are not cosmetic. They expose whether the company is organized around conviction or around optionality. 👉 Biotech fundraising rewards conviction backed by disciplined sequencing. When strategic discipline is present, the story tightens. Capital deployment becomes easier to defend. Milestones reinforce one another instead of competing for attention. Execution risk appears lower because effort is concentrated. 👉 Strategic overload, by contrast, forces founders to defend breadth. Strategic discipline allows them to defend depth. The difference is subtle internally. Externally, especially in biotech fundraising, it is decisive. Strategic Takeaway Strategic overload does not destroy a biotech company. It diffuses it. The danger is not visible failure. It is a diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before you start pitching. If capital, milestones, and narrative do not point in the same direction, investors feel it immediately. 👉 Strategy is not defined by how much you pursue. It is defined by what you are willing to exclude. ✅ Focus is commitment. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Discovery programs rarely fail because of one experiment. They stall when chemistry, modeling, and pharmacology drift apart. This week, we focus on integration — how to align scientific disciplines before costly translational decisions are made. Breakthroughs this week: 12th Adhesion GPCR Workshop (Düsseldorf, Sept 16–18, 2026); Free fatty acid receptor 2 allosterism is defined by cellular context; Conformational biosensors delineate endosomal G protein regulation by GPCRs. Dr. GPCR University Masterclass — Integrated GPCR Discovery in Practice Dr. GPCR University has been reorganized into a structured, navigable learning framework — and ten reformatted masterclasses are now live in this new architecture. These sessions span foundational pharmacology, receptor biology, modeling, translational strategy, and advanced GPCR decision logic. Each has been redesigned to function as part of a connected curriculum — not isolated content. All masterclasses — past and upcoming — are included with Premium Membership. New courses are delivered live, giving members the opportunity to ask questions directly to the instructors. Recordings are then made available inside the University library for continued access. Why this matters: Live engagement plus permanent access.  Ask your questions in real time — then revisit the material anytime. Structured continuity.  Move through a cohesive GPCR discovery framework, not disconnected lectures. Growing depth.  As new masterclasses launch, your access expands automatically. On March 12, the University returns live with a half-day session focused on integrated GPCR discovery across purinergic programs. Full details will be released soon. Faculty and their immediate teams receive one year of complimentary Premium Membership. Explore Dr. GPCR Masterclass ➤ Eurofins DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern GPCR discovery depends on more than hypotheses. It depends on infrastructure. We are thrilled to have entered a strategic partnership with Eurofins DiscoverX , a global provider of GPCR assay platforms and translational biology services covering more than 90% of the human GPCRome. Their capabilities span cAMP, β-arrestin recruitment, receptor internalization, calcium flux, ligand binding, and integrated discovery support — systems trusted across pharma, biotech, and regulatory programs. This partnership connects advanced assay and biology capabilities with the scientists and organizations positioned to use them — strengthening the bridge between platform expertise and program execution. Why this deserves attention: Assay breadth matters.  Platform selection shapes interpretation. Infrastructure influences velocity.  Scalable systems reduce downstream friction. Field alignment matters.  Industry-grade tools signal maturation of GPCR drug discovery. 👉 Read the Partnership Announcement ➤ Dr. GPCR Podcast — Lipid Rafts, Bitter Taste Receptors, and Context-Dependent Signaling In this episode of the DrGPCR Podcast, Keyvan Sedaghat joins the conversation to explore how membrane compartmentalization shapes GPCR signaling. From dopamine D1 receptor desensitization and GRK isoform specificity to lipid raft biology, the discussion highlights how membrane context reshapes receptor behavior. The episode also explores the open-access 7TMR-Raft database cataloguing GPCR–lipid raft associations and the expanding therapeutic landscape of extra-oral bitter taste receptors, including oncology implications. A recurring theme emerges: computational prediction is powerful — but wet-lab validation remains essential. As AlphaFold and molecular dynamics simulations accelerate hypothesis generation, disciplined experimental confirmation becomes even more critical. Why this matters: Membrane context changes signaling outcomes. Bitter taste receptors extend beyond taste biology. Prediction without validation creates risk. 👉 Listen to the Full Episode ➤ Why Dr. GPCR Premium Membership Gives You an Edge GPCR drug discovery is accelerating — across obesity, CNS, oncology, inflammation, and metabolic disease. Data volume is rising. Platform complexity is expanding. Interpretation risk is increasing. Dr. GPCR operates as a membership-based, nonprofit initiative — built to strengthen the GPCR field through structured access, curated intelligence, and connected expertise. Premium Membership unlocks: Masterclass  — Live and on-demand expert-led sessions, fully integrated into Premium. Weekly News  — Curated industry developments, classified publications, and signal-focused intelligence. Job Listings  — GPCR-specific career opportunities across academia, biotech, and pharma. GPCR Events  — Priority tracking of conferences and specialized meetings. Community Access  — Ask the Ecosystem, Happy Hour, and visibility across the GPCR network. Premium Members also receive a 50%+ discount on Terry’s Corner — unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin (for a limited time). To strengthen equitable participation across the field: Masterclass instructors and their immediate teams receive complimentary Premium access. Scientists living and working in developing countries can join for $25 per year — permanently set to ensure equitable global access. Institutional and team memberships receive discounted rates to support coordinated participation. This is not a content subscription. It is structured access to a field. It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions. When decisions compound, fragmented information creates drag. Structured access creates momentum. Premium delivers that — consistently. Join Dr. GPCR Premium — Build Your Structured Advantage ➤

Boston, MA and San Diego, CA — [February 18, 2026] — Dr. GPCR , the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. This partnership is designed to support the GPCR research community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident decision-making across the discovery and development continuum. Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most comprehensive GPCR assay portfolios, encompassing over 90% of the human GPCRome with assays for human receptors, species orthologs, and orphan receptors across various cellular backgrounds. Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical and biotechnology companies worldwide. Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification and validation to high-throughput screening (HTS), lead optimization, safety assessment, and regulatory-compliant potency testing. These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed publications and billions of screened data points. “Eurofins DiscoverX is distinguished by its deep GPCR expertise and close collaboration with customers,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR . “They offer more than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR research with confidence.” “Dr. GPCR plays a critical role in educating and connecting the global GPCR community,” said Geoffrey Donsimoni, GPCR Marketing Director at Eurofins DiscoverX . “Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world applications that help researchers fully leverage GPCR assay technologies across discovery and development.” Together, Dr. GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design and data interpretation. To explore Eurofins DiscoverX GPCR assay solutions and curated resources, visit: https://www.ecosystem.drgpcr.com/eurofins-discoverx To learn more about Dr. GPCR’s educational programs and global GPCR community, visit https://www.ecosystem.drgpcr.com About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem, Dr. GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery. About Eurofins DiscoverX Eurofins DiscoverX is a global leader in GPCR cell-based assay technologies, providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development. With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.

Drug discovery does not move in fixed conclusions. As datasets expand and systems are tested under new conditions, interpretations often require adjustment. What initially appears mechanistically clear can become more nuanced when additional experiments are layered in. Terry’s Pharmacology Corner is built around that reality. It is designed as a continuous learning environment — supporting scientific reasoning as programs mature, rather than treating pharmacology as a one-time lesson. The analysis below emerged from a recent live Ask Me Anything (AMA) session, where members brought forward active questions from their GPCR discovery efforts. The AMA format enables careful examination of evolving data — from Schild slope interpretation to probe dependence and kinetic validation — in real time. Through structured lectures, monthly live AMAs, and full replay access, the Corner provides ongoing refinement of pharmacological judgment across the lifespan of a program. The next live AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance to: terry@drgpcr.org Distinguishing Orthosteric vs Allosteric Mechanisms in GPCR Drug Discovery Programs Pharmacologists know the pressure of distinguishing between orthosteric and allosteric drug mechanisms—especially when structural data is unavailable. Functional assays can suggest clarity while quietly masking complexity, creating the illusion of competitive antagonism or obscuring subtle allosteric behavior. Misinterpretation does more than delay progress. It can redirect chemistry strategy, distort translational assumptions, and conceal liabilities that emerge only in vivo or in the clinic. What if a seemingly “clean” antagonist profile reflects silent allosteric modulation? What if probe dependence is quietly signaling selective safety implications? Each experimental decision — system sensitivity, assay configuration, kinetic design — carries strategic consequences. In this session, we explored: Strategic frameworks for early discrimination of orthosteric vs allosteric effects Conceptual tools for interpreting Schild plot deviations and probe dependence Operational practices that strengthen GPCR discovery pipelines Operationalizing Allosteric Signatures Early workflows often rely on rapid “one-way” experiments — screens that may reveal allosteric behavior but cannot definitively exclude it. A substantial rightward shift in a dose–response curve is frequently interpreted as competitive antagonism. However, negative allosteric modulators (NAMs) with modest cooperativity can mimic orthosteric competition across wide concentration ranges. The defining distinction is saturation: Saturation defines the allosteric boundary  — additional modulator produces no further shift. Orthosteric antagonists remain theoretically unlimited  — competition continues as concentration increases. Recognizing this difference early prevents mechanistic misclassification. Interpreting Schild Plots — Curves and Slopes Schild analysis remains foundational, but interpretation requires discipline. When a system approaches full allosteric occupancy, the Schild plot curves and the slope falls below unity — signaling that competitive assumptions no longer apply. Key diagnostic considerations: Curved Schild plots suggest occupancy-limited modulation Linear plots with slope ≠ 1 demand investigation  — equilibration time, receptor heterogeneity, or system-level factors must be assessed before mechanistic conclusions are drawn A slope is not merely a fitted parameter. It is a diagnostic signal. Probe Dependence — A Distinctive Allosteric Readout Allosteric systems exhibit probe dependence: the same modulator can shift one agonist thirty-fold and another six-fold. This variability is not noise — it is mechanistic information. Probe dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening strategy and therapeutic positioning As ligand diversity expands — including peptide agonists and biased ligands — ignoring probe dependence risks overlooking clinically meaningful distinctions. Assay Sensitivity and System Configuration Receptor expression level is a strategic variable. High-expression systems maximize detection sensitivity and can reveal subtle efficacies. Low-expression systems expose whether observed potency reflects intrinsic efficacy or simple binding strength. This “tissue volume control” becomes essential when: Distinguishing affinity-dominant from efficacy-dominant agonists Detecting silent partial agonism Extracting operational model parameters with translational relevance System configuration shapes interpretation. Decoding Kinetics — The Allosteric Differentiator Kinetic experiments provide definitive mechanistic evidence. Only allosteric modulators alter the onset or offset of agonist responses. Demonstrating changes in association or dissociation rates moves analysis beyond functional shifts toward mechanistic proof. Allosterics modify agonist kinetics Orthosteric competitors do not For publication-grade validation and regulatory confidence, kinetic evidence becomes indispensable. Strategic Use of Repurposing and Data Controls Drug repurposing offers reduced uncertainty and extensive prior data. Yet rare adverse effects may only emerge after large-scale exposure, and selectivity must still be demonstrated rigorously. Meanwhile, controls remain non-negotiable. GPCR systems are sensitive and context-dependent. Pathway bias, tissue sensitivity, and system artifacts can distort interpretation if not carefully managed. Robust controls distinguish mechanism from artifact Multipathway analysis reduces false confidence Neglecting these elements invites downstream surprises. Integrating Chemistry and Kinetics Early Biological activity alone does not define a viable series. Chemical tractability, early safety screens (e.g., hERG), ADME properties, and residence time often determine long-term success. Potency can attract attention, but residence time and target engagement kinetics frequently better predict in vivo performance. Strategic discipline means: Screening liabilities early Integrating chemistry insights immediately Avoiding advancement of scaffolds likely to collapse later “Fail early” is not pessimism. It is resource stewardship. Best Habits for Data Quality and Reproducibility Detection assays identify activity; they do not validate therapeutic viability. Repetition without purpose consumes time. Statistical rigor prevents wishful interpretation. Quantitative follow-up studies separate true signal from noise. Advance promising hits into mechanistic evaluation quickly Use statistics to arbitrate interpretation Design assays deliberately Interpretive discipline is the foundation of reproducible pharmacology. Why Terry’s Pharmacology Corner Mechanistic understanding evolves. What appears settled under one experimental condition may require refinement under another. Terry’s Pharmacology Corner provides a structured environment for that evolution: Weekly advanced pharmacology lectures Monthly live AMAs for real-time scientific discussion A continually expanding on-demand archive Sustained exposure to disciplined mechanistic reasoning The value lies not in a single explanation, but in maintaining interpretive rigor as programs mature. Forty years of pharmacological expertise — organized into a year-round learning framework for serious GPCR scientists. Explore the full library ➤

👉 Most biotech founders  do not realize they are in trouble when the money runs out. By then, the situation is already decided. 👉 The real issue begins earlier, at a point where the company is still operating, the science is progressing, and milestones are being met. On paper, things look fine. In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Conversations move from options to assumptions. Questions about timing become harder to answer with confidence. 👉 How long can we operate if fundraising takes longer than expected? Which decisions can we still reverse, and which ones are already locked in? This is not a cash crisis yet. It is a loss of financial control . Biotech founders rarely notice this moment because nothing visibly breaks. There is no single bad hire, no failed experiment, no dramatic mistake. Progress continues, but clarity quietly erodes . 👉 The danger is not that money disappears overnight. The danger is that financial visibility fades while the company keeps moving forward , until choices are driven by urgency rather than strategy. 👉 This blog focuses on that specific problem. Why biotech founders lose financial control without seeing it coming, and what has to be in place early enough to prevent that loss before options disappear . For Biotech Founders, the real danger is not running out of money, but losing financial control early enough that every later decision becomes forced. Why biotech founders do not see the warning signs early enough 👉 The core problem is not that biotech founders ignore their finances. It is that they rely on the wrong signals to tell them whether the company is healthy. In early-stage biotech, progress is measured through science. Experiments advance. Data improves. Technical milestones are reached. These signals are visible, concrete, and emotionally reassuring. 👉 They create the feeling that things are working. What often goes unnoticed is that financial signals behave very differently. Cash flow problems do not announce themselves loudly. They lag behind decisions. They surface only after commitments have already been made. Hiring decisions feel justified because the science is moving. Vendor contracts feel reasonable because the roadmap looks ambitious. Each choice makes sense in isolation. 👉 Together, they quietly reduce flexibility. This is where many biotech founders lose visibility. They track burn rate, but not decision reversibility. They know how many months of runway remain, but not which strategic options are already gone . The real warning signs are not financial numbers. They are strategic signals. 👉 When timelines stop being adjustable. 👉 When costs become hard to unwind. 👉 When fundraising shifts from opportunity to necessity. Because these changes happen gradually, they rarely trigger an alarm. Progress continues, activity stays high, and urgency feels manageable. By the time concern turns into action, financial control has already weakened. 👉 The issue is not a lack of intelligence or discipline. It is that biotech founders are trained to trust scientific momentum , while financial risk builds silently in the background. The solution starts with recognizing that financial control is not about tracking money , but about maintaining optionality early enough to act. Burn rate creates the illusion of control 👉 Many biotech founders  believe they are in control because they can clearly explain their burn rate. They know how much the company spends each month, how long the runway looks on paper, and how these numbers change over time. This creates a sense of certainty that feels reassuring, especially when shared with investors or the board. The problem is that burn rate measures spending, not freedom. It tells you how fast cash is leaving the company, but it does not tell you how many meaningful choices are still available. 👉 As the company moves forward, costs slowly become harder to reverse. Hiring decisions lock in fixed expenses. Vendor agreements commit the team to specific timelines. Infrastructure choices narrow future paths. From a distance, everything still looks manageable. Runway exists. The math checks out. Yet financial control is already weakening , because the company is becoming less flexible with every committed decision. 👉 This is where many biotech founders misread the situation. They focus on extending the runway instead of protecting optionality. They manage cash flow, but they do not actively track which strategic decisions can still be changed and which ones are already locked in. The shift that matters is not more detailed reporting. It is a change in perspective. ✅ Financial control is about knowing how much room remains to change direction.   Control fades before cash. The moment biotech founders lose flexibility is long before the bank account becomes the problem. When building quietly turns into surviving 👉 At a certain point, many biotech founders  believe they are still building the company, while in reality, they have already shifted into survival mode. This transition rarely happens consciously. It emerges gradually, through small changes in how decisions are made. The science continues, but the intent behind decisions changes. Roadmaps stop being tools for choice and start becoming tools for justification. Fundraising discussions move from strategic timing to urgent necessity. Planning becomes defensive. This shift usually shows up in very specific ways. 👉 Biotech Founders know they are no longer fully in control when: 1️⃣ Decisions are evaluated primarily by cost, not by strategic value 2️⃣ Short-term deliverables consistently override long-term positioning 3️⃣ Hiring and partnerships are delayed, not by strategy, but by fear of cash burn 4️⃣ Fundraising becomes the main plan instead of one option among several None of these signals means the company is failing. They mean something more subtle. The company is reacting instead of choosing. This is the moment where financial control is effectively lost. Not because the money is gone, but because the company no longer has the freedom to pursue its best options. By the time 👉 Biotech founders recognize this shift; most strategic paths are already constrained. Regaining control requires catching this transition early, before survival thinking becomes the default operating mode. Where biotech founders lose the chance to regain control 👉 The loss of financial control rarely happens in one dramatic moment. It happens when biotech founders delay confronting uncertainty , because nothing feels urgent enough yet. As long as experiments continue and milestones move forward, it is easy to assume there is still time. Decisions get postponed in the hope that the next data readout, the next partnership, or the next funding conversation will resolve the pressure. This mindset quietly shifts responsibility from leadership to timing. 👉 The critical mistake is not overspending. It is waiting too long to make strategic trade-offs . At this stage, Biotech Founders often focus on protecting momentum instead of restoring clarity. They keep the roadmap intact even when assumptions have changed. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting failure. In reality, this is the last window where control can still be regained. The solution is not drastic cuts or panic-driven decisions. It is an early strategic intervention . Reexamining commitments while they are still reversible. Stress test the plan against slower fundraising scenarios. Separating essential progress from activity that only signals progress. ✅ Financial control returns when Biotech Founders stop asking how to last longer and start asking which decisions must remain flexible in the next six months . That shift creates space to act deliberately again, rather than being pushed forward by circumstances. Strategic takeaway 👉 For biotech founders , financial failure rarely starts with an empty bank account. It starts when financial control fades without being noticed . 👉 The key shift is not better reporting or more frequent fundraising. It is earlier strategic clarity.  Knowing which decisions must remain reversible and which assumptions need to be challenged before pressure forces the answer. ✅ Biotech founders who protect optionality early keep the ability to choose. Those who do not end up reacting. ✅ Control is about how early clarity is regained. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal detection. If you work in GPCR research, clarity is leverage. The ability to access the right framework, detect risk early, and act on emerging signals determines whether programs accelerate—or stall. This week’s issue focuses on structure, early safety strategy, and the next wave of signal transduction research. Each piece is designed to help you make better decisions—faster. 🔍 This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly oral GLP-1 maintenance data; Enveda IND clearance ENV-308; Zealand explores brain-directed obesity therapies. Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Discovery Summit. Career opportunities: Senior Scientist roles; Postdoctoral GPCR positions. Must-read publications: D2 receptor constitutively active mutants; β2AR allosteric SERS assay; CXCR4 inhibitor burixafor Phase 2. Dr. GPCR University — Reorganized for Clarity and Speed The Dr. GPCR University has undergone a structural redesign. This soft launch prioritizes usability and clarity to support stronger GPCR drug discovery decisions across teams. You can now search courses by level, topic, or instructor. Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages. Full course videos stream directly from the platform, and downloadable resources are available in one place. Legacy courses will migrate into this format over the coming weeks, with live courses returning in March. In the meantime, Premium members continue to have full access to the legacy course pages. Why this matters now: Stop wasting time hunting for relevant training across fragmented platforms. Align your team around structured learning outcomes, not scattered slide decks. Identify the exact knowledge gap slowing your program—and close it efficiently. All courses remain included in Premium Membership. Preview the full University experience ➤ Already a Premium Member? Start learning here ➤ Terry’s Corner — Early Safety Assays For Better GPCR Drug Discovery Decisions Too many discovery programs fail because early safety signals were underestimated—or missed entirely. In this session, Dr. Terry Kenakin walks through the core early assays that protect your chemistry, budget, and timeline. This is not theory. It is operational pharmacology designed to prevent avoidable setbacks. Early safety frameworks directly influence GPCR drug discovery decisions, especially when timelines and capital are tight. What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags. Interpret cytotoxicity data correctly—distinguish transient stress from meaningful off-target damage. Assess hepatotoxicity risk—anticipate reactive metabolites and high-risk drug–drug interactions. Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME, and experimental design. It delivers repeatable depth far beyond a short-format workshop. An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST. Subscribe to the free Kenakin Brief Newsletter to join the AMA . Premium Members get 50%+ discount when they join Terry’s Corner. Access this week’s safety framework ➤ GPCRs: Signal Transduction — Volume II (Call for Papers, Deadline March 14) Signal transduction remains central to understanding GPCR biology across health and disease. A new volume dedicated to GPCR signal transduction invites contributions spanning cellular biochemistry, mechanistic signaling, and translational implications. Submissions are welcome across formats including Original Research, Reviews, Methods, Perspectives, Hypothesis and Theory, Technology and Code, and more. This initiative brings together field experts to advance collective understanding of how GPCR-mediated signaling shapes physiology and pathology. Given the pace of mechanistic and structural insight emerging across the field, coordinated scholarly contribution is timely. Why consider contributing: Position your work within a focused, visible GPCR signaling collection. Contribute to shaping scientific direction in cellular biochemistry. Strengthen field-wide dialogue around signaling mechanisms and dysfunction. Submit your work today ➤ Why Dr. GPCR Premium Membership Gives You an Edge GPCR science is accelerating across obesity, CNS, oncology, and metabolic disease. More data. More companies. More noise. Premium Membership filters that complexity — without filtering out what matters. Each week, you receive curated, signal-focused intelligence: industry developments, classified publications, priority event tracking, curated career opportunities, and full access to Dr. GPCR University courses — now included in Premium. That means structured, searchable, expert-led training across levels and topics — without additional course fees. Premium Members also receive a 50%+ discount on Terry’s Corner , unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin at a significantly reduced cost. This is not commentary. It is structured access and structured education. Premium supports more confident GPCR drug discovery decisions by helping you: Detect meaningful shifts early — without wading through noise. Strengthen mechanistic understanding through organized expert frameworks. Equip your team with repeatable training resources in one place. Reduce external training spend while increasing scientific depth. It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions. When decisions compound, scattered information creates drag.Structured access creates momentum. Premium delivers that — consistently. Explore Premium Today ➤

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What actually happens is more subtle. Urgency replaces direction, and short-term signaling begins to outweigh long-term thinking. This is where most biotech startup fundraising mistakes are born, not from lack of intelligence or discipline, but from the belief that fundraising decisions exist outside the core strategy. 👉 In reality, every fundraising-driven adjustment leaves a structural mark on how the company operates, prioritizes, and allocates attention. Over time, these small shifts accumulate. Milestones are chosen for narrative strength rather than strategic leverage. Hiring decisions are pulled forward to support a story. Hard tradeoffs are delayed instead of resolved. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech startups. ✅ This post explores why fundraising mistakes have such a disproportionate impact on biotech companies, how these patterns emerge in otherwise well-run teams, and what founders can do to keep fundraising from taking control of their strategy. 👉 If you are preparing to raise, currently fundraising, or reflecting on a recent round, this is an opportunity to recognize where pressure may already be shaping decisions more than strategy should. Fundraising rarely breaks biotech startups overnight. It quietly reshapes decisions, long before the damage becomes visible. Fundraising turns strategy into reaction 👉 Fundraising rarely enters a biotech startup as a strategic decision-making framework. It enters as pressure. Pressure to show progress. Pressure to justify valuation. Pressure to appear confident about the future. And under pressure, even strong teams begin to confuse movement with direction. 👉 In early-stage biotech, this confusion is especially dangerous. Scientific progress already moves slowly, uncertainty is unavoidable, and timelines stretch far beyond what most investors are comfortable with. 👉 When fundraising begins, founders often respond by accelerating visible activity rather than strengthening underlying strategy. This is where one of the most common biotech startup fundraising mistakes takes root. Decisions stop being evaluated based on long-term leverage and start being filtered through a single question. Will this help the raise? 👉 When that question becomes dominant, strategy quietly shifts from intentional design to reactive justification. Teams begin to prioritize what can be explained easily over what actually matters most. Milestones are selected for narrative clarity rather than strategic necessity. Roadmaps bend toward what sounds fundable instead of what creates durable value. 👉 Over time, the company becomes highly responsive but increasingly misaligned. What makes this pattern so hard to catch is that it feels productive. Meetings increase. Slides improve. Activity intensifies. Yet clarity erodes, because reaction has replaced deliberate choice.   👉 Strong biotech startups do not fail at this stage because they stopped working hard. They fail because they stopped deciding with purpose. How biotech startup fundraising mistakes actually show up 👉 Fundraising mistakes rarely appear as obvious errors. In strong biotech startups, they surface as reasonable adjustments that seem aligned with reality. This is what makes them so difficult to recognize while they are happening. 👉 Under fundraising pressure, decision-making slowly shifts. Founders do not deliberately abandon strategy. Instead, they begin to evaluate choices through a narrower lens. What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech startup fundraising mistakes most often show up as the following patterns: Milestones are chosen for narrative clarity rather than strategic leverage.   Experiments are prioritized because they fit a clean story, not because they meaningfully reduce scientific or commercial risk. Hiring decisions are accelerated to signal momentum.   Roles are added to demonstrate scale, even when the organization is not structurally ready to support them. Scientific priorities are reshaped to meet investor expectations.   Programs move forward because they sound fundable, not because the data justifies the timing. Hard strategic tradeoffs are postponed.   Founders delay narrowing focus, hoping clarity will emerge after the round instead of designing it upfront. Internal alignment weakens beneath visible progress.   Teams execute faster but understand less clearly why certain priorities exist, creating silent friction. 👉 Each of these decisions can be defended in isolation. The damage comes from their cumulative effect , when short-term fundraising logic quietly replaces deliberate strategy. 👉 This is why strong biotech startups often appear busiest right before they lose momentum. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Clarity does not follow funding. Funding follows clarity. Why fundraising mistakes reshape the company before anyone notices Most biotech founders assume that fundraising mistakes show up as visible failures. A missed round. A rejected pitch. A broken investor process. In reality, the most damaging mistakes rarely appear at the surface. 👉 They take shape much earlier, inside the logic of everyday decisions, long before fundraising outcomes are known. Fundraising introduces a specific kind of cognitive pressure. It rewards confidence over uncertainty, clarity over complexity, and momentum over reflection. Under these conditions, decision making begins to shift subtly. Choices that simplify the story are favored over choices that preserve strategic truth. Decisions that reduce tension are prioritized over decisions that resolve it. 👉 The company does not become careless. It becomes selectively blind. As this pattern repeats, the organization adapts. Teams learn which questions are welcomed and which ones slow things down. Scientific nuance starts to feel inconvenient. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often just the absence of friction, and friction disappears not because issues are solved, but because they are avoided. This is how biotech startup fundraising mistakes embed themselves into the operating system of the company. They are not single wrong calls, but accumulated shifts in how decisions are framed and justified. By the time founders sense that something feels off, the logic has already normalized. 👉 The company is still moving, still executing, but no longer questioning the direction with the same rigor. This is why strong biotech startups can lose their strategic center without any dramatic turning point. Nothing breaks all at once. Instead, clarity erodes quietly, decision by decision, under the assumption that everything will be fixed after the round closes. What actually prevents fundraising mistakes from taking over Most biotech founders try to solve fundraising-related problems by improving execution. Better decks. Clearer narratives. Tighter timelines. 👉 What they often miss is that execution quality does not protect strategy when the decision logic itself is unstable. The companies that avoid destructive fundraising mistakes do not do so because they raise faster or pitch better. They do it because they anchor fundraising inside a stronger strategic structure. 👉 That structure usually rests on a small number of non-negotiable principles. 1️⃣ They define strategic truth before investor truth. 👉 High-performing biotech teams are explicit about what must be true for the company to succeed, independent of how attractive that story sounds externally. Fundraising adapts to this reality, not the other way around. 2️⃣ They separate progress from presentation. 👉 These teams distinguish clearly between work that advances the company and work that merely explains it. Investor readiness never becomes the primary filter for scientific or organizational decisions. 3️⃣ They make hard tradeoffs early and visibly. 👉 Instead of postponing narrowing decisions until after a round, they resolve them upfront. This reduces internal ambiguity and prevents fundraising pressure from reopening questions that were already strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases, they slow down decision-making rather than accelerate it. Additional scrutiny is applied exactly where urgency would normally shortcut thinking. What unites these behaviors is not discipline for its own sake, but intent. Fundraising remains a tool, not a steering mechanism.  Strategy continues to shape decisions even when external pressure rises. ✅ This is the point where biotech startup fundraising mistakes stop accumulating. Not because risk disappears, but because decisions remain grounded in a framework that fundraising cannot easily distort. Strategic Takeaway 👉 Strong biotech startups are rarely destroyed by a single bad fundraising decision. They lose their edge when fundraising quietly becomes the logic behind everyday choices , replacing strategy with serving it. 👉 The difference between companies that survive fundraising pressure and those that drift is not discipline or ambition. It is whether decision-making remains anchored in a clear strategic framework before, during, and after the raise . Fundraising should amplify direction, not define it. When strategy leads, and fundraising follows, capital becomes leverage. When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. ✅ The real work is not raising better. The real work is deciding clearly before pressure decides for you. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold to a complete halt. Rushing past early safety signals, especially those emerging from cytotoxicity or off-target activities, risks catastrophic consequences for both patient safety and project resources. The pressure mounts further as regulators require detection and characterization of these liabilities—even when they emerge rapidly or unpredictably. The strategic challenge is knowing which early assays are truly non-negotiable, which mechanisms demand immediate attention, and how to build robust decision points into the cascade without falling into the trap of overtesting or false reassurance. In this session, you’ll gain: Clarity on high-impact early safety assays and their compelling rationale Understanding of toxicological mechanisms shaping go/no-go choices Strategic insights into early identification and mitigation of drug liabilities Game-Changing Early Safety Assays Certain toxicological activities, if identified in a compound scaffold, are strategic showstoppers. In the full lecture, Dr. Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such as hERG inhibition or mutation induction—long before a candidate enters the clinic. These tests transform discovery cascades by distinguishing navigable risks from non-starters. Highly selective filters can streamline resource allocation Early elimination of unsafe scaffolds prevents late-stage attrition hERG and Cardiac Risk hERG potassium channel inhibition represents a fatal toxic liability, rapidly precipitating ventricular fibrillation. Dr. Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have evolved to prioritize this critical safety gate. A scaffold exhibiting hERG inhibition is an immediate candidate for discontinuation, as the risk is both acute and universally unacceptable. hERG testing is non-negotiable in early discovery Assay sensitivity balances speed and clinical relevance Mutation Induction and the Ames Test Mutagenicity stands as another barrier. The Ames test, a foundational bacterial assay, surfaces as an early alert for DNA-modifying liabilities. The full lecture describes how this assay serves as a one-way filter: positive results necessitate project termination, while negatives invite further but cautious progression. Single-point thresholds for halting progression Cannot wholly exclude latent risks with a negative result Cytotoxicity and Off-Target Screening Compounds are systematically challenged in vitro against a spectrum of cellular targets—enzymes, receptors, transporters—to expose off-target activities and unintended cytotoxic effects. Dr. Kenakin stresses that multi-parametric cell-based assays highlight hidden threats, from membrane disruption to mitochondrial impairment, demanding robust, multitiered screens in the discovery workflow. Cytotoxicity is multifactorial and mechanism-dependent Early in vitro screens save time by revealing broad liabilities Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of orally administered compounds, remains a sentinel for generalized toxicity. Dr. Kenakin clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven by drug-drug interactions, must be interrogated at this stage. The emphasis is on predicting and averting the generation of reactive metabolites capable of irreversible harm. Liver-centric assays identify primary and secondary toxic mechanisms Reactive metabolite detection is vital for long-term safety Reactive Metabolites and Irreversible Damage Formation of reactive metabolites that alkylate proteins or nucleic acids can result in permanent organ dysfunction. Dr. Kenakin demonstrates how mechanistic assays allow for early warning, ensuring that compounds prone to generate such species are deprioritized or redesigned before entering expensive development stages. Irreversible modifications pose ongoing risks for safety profiles Proactive detection methodology arms discovery teams with actionable insight Pharmacokinetic and High-Dose Investigations Regulatory guidance requires toxic effects to be observed—if achievable—at sufficiently high concentrations. Pharmacokinetic approaches are adapted, sometimes employing exotic carriers or solvents to maximize exposure. Dr. Kenakin details how discovery teams can leverage atypical conditions to elucidate liabilities and satisfy regulatory scrutiny. Purpose-driven exposure strategies enhance detection Unique pharmacokinetics may be required for robust toxicology In Silico Toxic Signals Advancements in computational screening enable teams to avoid chemotypes associated with known toxicity ("toxicophores"). Dr. Kenakin acknowledges the increasing utility of in silico alerts in early decision-making, arming medicinal chemists and project leaders with tools to preempt costly wet-lab dead ends. Red-flagging toxicophores accelerates rational design cycles Computational prediction complements biological screening Why Terry’s Corner Terry’s Pharmacology Corner delivers weekly in-depth lectures by Dr. Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery fundamentals, challenging entrenched assumptions, and strengthening preclinical pipelines. As GPCR science and pharmacological innovation accelerate, timely guidance from foundational to advanced concepts has never been more urgent. 40 years of expertise at your fingertips: Explore the full library ➤ Or preview what’s inside: Read the latest articles ➤ 40 years of expertise at your fingertips : Explore the full library ➤

If you’ve felt the pace of GPCR research accelerating—and the signal getting harder to separate from the noise—you’re not alone. This week marks the start of a new era for the Dr. GPCR Ecosystem: sharper programming, deeper expertise, and renewed momentum across everything we publish and build. After a brief pause over the holidays and last month, we’re back in full force—designed to help you make better scientific and strategic decisions, faster. Latest breakthroughs :  Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition; 2025 Fellows announced, including Dr. Terry Kenakin ; GIP receptor agonist patent WO2025264700. 🔍 This Week in Dr.GPCR Premium: Sneak Peek Upcoming events:  5th GPCRs Targeted Drug Discovery Summit, Boston. Career opportunities:  In vitro Pharmacology Research Assistant—Geneva. Must-read publications:  GPCRs in neurological disorders; OSTα-OSTβ structure; GPCR–G protein–β-arrestin megacomplex. A New Era for the Dr. GPCR Ecosystem The Ecosystem has been evolving over the years—expanding into an integrated platform for learning, insight, and connection. We have shifted to continuous, coordinated programming  across Weekly News, Terry’s Corner, the Podcast, and now the Dr. GPCR University. This isn’t about more content. It’s about better alignment : helping scientists, drug hunters, and decision-makers stay grounded in fundamentals while keeping pace with modern GPCR research and drug discovery. What this new phase delivers: Continuity across formats  — concepts reinforced through articles, lectures, and conversations. Clearer signals  — curated insights that reduce noise without oversimplifying complexity. Community presence  — from conferences to collaborative initiatives built in public. 👉 Email us to chat, collaborate and tell us what you need ➤ Terry’s Corner—Basic Pharmacokinetics Pharmacokinetics isn’t a late-stage checkbox—it’s a decision framework that shapes every viable drug discovery program. In this lesson, Dr. Terry Kenakin reframes PK as a predictive, manageable discipline , not an unavoidable bottleneck. Rather than chasing potency alone, this session equips drug hunters with system-level thinking: how ADME properties govern exposure, efficacy, and safety long before clinical translation. Why this matters now: PK defines translatability  — activity without exposure is not pharmacology. Optimization is modular  — activity, ADME, and safety can be tuned independently. Early assays prevent late failure  — modern in vitro tools dramatically reduce attrition . Want to learn more? Here's how: Watch the course trailer ➤ Read the blog post ➤ Subscribe to the Kenakin Brief ➤ Dr. GPCR Podcast—GPCR Assay Strategy, Bias, and Translational Drug Discovery In this episode of the Dr. GPCR podcast , Dr. Martin Marro shares hard-earned lessons from the interface of assays, bias, and translation. The conversation moves beyond theory into real-world tradeoffs: fluorescence-based assays, internalization readouts, antibody discovery, and the persistent gap between in vitro promise and in vivo reality. Listeners will gain perspective on: Assay choice as strategy , not convenience. Bias agonism pitfalls  that emerge during translation. Leadership decisions  that keep multidisciplinary teams aligned. 👉 Listen to the full conversation ➤ Why Dr. GPCR Premium Membership Gives You an Edge Dr. GPCR Premium is designed for scientists and teams who can’t afford to chase every headline—or miss the ones that matter. Premium delivers curated, noise-free intelligence every week : expert lectures, classified industry updates, upcoming events, career opportunities, and insider commentary. Instead of fragmented inputs, members get a coherent view of the GPCR landscape—connecting fundamentals to application, and research signals to real-world decisions. Your membership also supports open educational resources for the global GPCR community, ensuring depth, rigor, and accessibility remain central to the field. FAQ 🔹 What’s included? The complete Weekly News digest, curated jobs and events, classified GPCR publications, on-demand expert frameworks, GPCR University access, and member-only discounts. 🔹 Who is it for? GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need fast, relevant intelligence to stay ahead. 🔹 Why now? GPCR innovation is accelerating. Those acting on the right signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming. 👉 Join the Ecosystem ➤ Already a Premium Member? 👉 Access this week’s full Premium Edition here ➤ From the Community “Great initiative—clear guidance on career paths, choosing research topics, switching fields, and learning from both failures and successes.” This is just the beginning. With new courses, expanded programming, upcoming partnerships, and deeper community engagement ahead, the Dr. GPCR Ecosystem is entering its most ambitious phase yet. If you want to stay informed, connected, and prepared for what’s next in GPCR science—now is the moment to step in. 👉   Email Us ➤ Yamina and the Dr. GPCR Team

Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. A bad hire. A missed partnership. 👉 Biotech startup failure is usually imagined as a moment where something clearly breaks. In reality, many biotech startups drift into trouble without ever making a single decision that looks wrong at the time. Progress continues. Data improves. Teams stay busy. And yet, momentum slowly fades. 👉 This is what makes biotech startup failure so difficult to recognize early . There is no obvious mistake to point to. Each decision feels reasonable in isolation. Each step forward appears justified. The problem is not one bad move, but the quiet accumulation of many small choices that are never evaluated as a system. 👉 Founders often look back and say that nothing felt broken. The science was sound. The strategy seemed logical. Execution moved forward. The danger was not error, but drift. When direction is not continuously reinforced, organizations begin to slide off course without noticing. Priorities shift slightly. The scope expands gradually. Focus erodes without triggering alarms. By the time leadership senses friction, the underlying causes are already structural. 👉 Biotech startup failure rarely announces itself loudly.   It emerges slowly, through alignment gaps that grow while everyone believes they are doing the right thing. 👉 This article examines how biotech startups drift into failure without obvious mistakes , and why preventing that drift requires a different kind of leadership awareness than most founders expect. Sustainable biotech growth depends on leaders reinforcing direction as decisions accumulate, not on perfect judgment. How Rational Decisions Accumulate Into Drift 👉 Every biotech startup is built on decisions that make sense in the moment. One more experiment to reduce risk. One more indication to keep options open. One more discussion before committing. None of these choices looks wrong on its own. 👉 This is how biotech startup failure often begins , not with a mistake, but with a pattern. Each decision is rational in isolation, yet no one steps back to evaluate how those decisions interact over time . Direction is assumed instead of actively reinforced. Founders naturally optimize for what feels responsible. Reducing uncertainty. Preserving flexibility. Avoiding premature commitment. 👉 Over time, these choices quietly dilute focus, slow momentum, and blur strategic intent. Drift does not require poor judgment. It emerges when decisions are made without a shared directional reference. Teams continue executing. Progress remains visible. But alignment weakens as priorities soften and scope expands. This is why biotech startups can feel productive while moving off course. Meetings are full. Roadmaps evolve. Data improves. Activity creates the illusion of progress while direction quietly erodes. 👉 Biotech startup failure rarely comes from one wrong decision.  It forms when many reasonable decisions are never examined as part of a system. Why This Type of Biotech Startup Failure Is Hard to Detect 👉 What makes this form of biotech startup failure  especially dangerous is how quiet it is. There is no obvious crisis. No single decision feels reckless. No moment where leadership can clearly say that something went wrong. Instead, everything appears reasonable. Progress continues. Teams remain engaged. Results still arrive. 👉 Early signals often look positive, which delays recognition of the deeper problem. Founders tend to look for failure in the wrong places. They search for flawed assumptions, weak data, or execution gaps. But drift does not live there. It lives in what is never questioned because it feels acceptable at the time. 👉 This kind of failure is hard to detect because it hides behind familiar patterns: Incremental scope expansion that feels strategic Delayed commitments are justified as prudent Busy teams without a shared directional anchor None of these raises alarms on their own. Together, they slowly reshape the company without deliberate intent. 👉 Another reason this drift goes unnoticed is that responsibility is diffuse. No one decision owns the outcome. No single leader feels accountable for the trajectory. The absence of clear error creates the illusion of control. By the time misalignment becomes visible, it often shows up indirectly. Execution feels heavier. Decisions take longer. Tradeoffs become harder to articulate. At that point, the issue is no longer tactical. It is structural. 👉 Biotech startup failure of this kind is difficult to spot precisely because nothing ever appears obviously wrong. Biotech startups stay on course when teams align decisions around a clearly reinforced direction. Where Execution and Strategy Quietly Fall Out of Sync As drift accumulates, the first visible cracks appear between strategy and execution. On paper, the strategy still exists. Roadmaps are updated. Priorities are discussed. But execution slowly stops reflecting strategic intent . 👉 Teams continue to move forward, yet not in a converging direction. Research advances. New initiatives start. Additional questions are explored. Activity increases while coherence declines . What looks like progress is often motion without alignment. This is where biotech startup failure becomes operationally real . Decisions take longer because the context is unclear. Tradeoffs resurface repeatedly because they were never settled. Teams hesitate, not because they lack capability, but because they lack direction. Founders often sense this as friction rather than failure. Meetings feel heavier. Communication requires more explanation. Alignment needs constant reinforcement. ✅ The organization is working harder to achieve less clarity . The most damaging aspect of this phase is that it still feels manageable. Nothing has collapsed. Metrics may even look acceptable. But execution is no longer pulling the company toward a single outcome . It is responding to competing signals that were never reconciled. When strategy and execution drift apart, the startup does not stop moving. It moves sideways. Over time, this sideways motion becomes costly, both financially and organizationally. 👉 By the time leadership recognizes the gap, correcting course requires far more effort than preventing the drift would have. This is how biotech startups find themselves misaligned without ever abandoning their original intent. The Leadership Shift That Prevents Drift Before It Becomes Failure Preventing this form of biotech startup failure  does not start with fixing execution details. It starts with a leadership shift. ✅ Founders must stop evaluating decisions individually and start managing the pattern those decisions create over time. The solution is not to slow down or become more cautious. It is to make direction explicit and repeatedly reinforced , so that reasonable decisions accumulate toward the same outcome instead of pulling the organization apart. This requires a small number of deliberate leadership practices that create clarity before drift turns into failure. ✅ Effective leaders consistently do the following: 1️⃣ Define a clear directional priority for the current phase.  Not a vague vision, but a concrete answer to what matters most right now. Speed, validation, partnership readiness, or focus. When this is clear, decisions align naturally. 2️⃣ State what the organization is intentionally not optimizing for.  Drift accelerates when everything feels important. Naming what is deprioritized removes silent tension and reduces unnecessary expansion. 3️⃣ Treat strategic decisions as settled until explicitly reopened.  Execution slows when teams assume every choice is provisional. Clear commitments allow progress without constant re-justification. 4️⃣ Regularly examine decisions as a system, not as isolated events.  Leaders must ask whether recent choices still point in the same direction. This prevents rational decisions from compounding into misalignment. 5️⃣ Translate direction into simple execution signals.  Teams need to know how priorities show up in daily work, milestones, and resource allocation. Clarity at the top must become clarity in action. 👉 When these practices are in place, drift becomes visible early. Small misalignments are corrected before they harden. Execution regains coherence because direction is actively maintained, not assumed. This leadership shift does not eliminate uncertainty. It does something more important. It ensures that uncertainty does not quietly redirect the company without conscious choice. ✅ Biotech startups that avoid silent failure are not the ones that make perfect decisions. They are the ones who manage direction deliberately as decisions accumulate. Strategic Takeaway 👉 Biotech startup failure is rarely caused by one wrong decision.  It is caused by a direction that is not actively maintained as decisions accumulate. When every choice is evaluated in isolation, drift becomes inevitable. Progress continues. Effort increases. Yet alignment quietly erodes. 👉 The absence of obvious mistakes creates a false sense of safety. The strategic advantage lies in leadership attention, not precision. Founders who prevent silent failure do not wait for problems to surface. ✅ They continuously reinforce direction and make the cumulative impact of decisions visible. Clarity is not a one-time act. It is a repeated discipline. When leaders manage direction deliberately, reasonable decisions compound into momentum instead of drift. ✅ Are your recent decisions still pointing in the same direction, or are they quietly pulling your biotech startup off course? Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

In modern drug discovery, the promise of precision medicine often collides with the reality of unpredictable pharmacokinetics . Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue distribution, or unanticipated clearance . Although major advances in predictive tools have reduced PK-driven attrition, misconceptions about ADME (absorption, distribution, metabolism, excretion)  persist across discovery teams. Too often, fundamentals are undervalued: in vitro assays are treated as routine checkboxes, and ADME is mistakenly assumed to track with activity or safety. When PK is misunderstood early, Dr. Kenakin argues, every downstream variable becomes distorted —from preclinical modeling to dose selection and late-stage efficacy. In This Session, You’ll Gain Clarity on how ADME governs translational success A deeper understanding of scaffold independence in PK and safety optimization A renewed framework for asking the four core questions of drug movement Debunking the pharmacokinetics Bottleneck Despite technological leaps, pharmacokinetics is still often mischaracterized as a “solved” problem. In the late 20th century, nearly half of investigational drugs failed due to inadequate PK. Predictive in vitro assays have dramatically reduced this attrition—but with success comes complacency . PK errors no longer dominate failure statistics, but fundamental blind spots still derail programs Every therapeutic area—CNS, cardiovascular, GI—faces the same core PK constraints Dr. Kenakin challenges the assumption that “good enough” tools guarantee progress, emphasizing that judgment and experimental framing still matter PK is no longer the bottleneck it once was—but ignoring fundamentals creates rare, high-impact failures . The Independence of Drug Attributes Primary activity, ADME, and safety form three independent axes of drug optimization . Crucially, altering one does not inherently change the others—a principle often overlooked in early discovery. The IGF-1 scaffold example demonstrates how CYP450 liabilities were mitigated without compromising efficacy This independence empowers chemists to optimize safety or PK without sacrificing target engagement Optimization should be modular, not monolithic Medicinal chemistry succeeds fastest when teams stop assuming trade-offs that don’t actually exist. The Four Fundamental Questions of PK All pharmacokinetic strategy reduces to four deceptively simple questions: How much of the administered dose reaches systemic circulation? Where does the drug distribute once inside the body? How long does it persist at the target site? How frequently must it be dosed to maintain effective exposure? Across therapeutic classes, Dr. Kenakin shows that programs fail when these questions are skipped, deferred, or answered implicitly instead of experimentally . Drug-Like Properties: The Real Starting Point PK does not begin at dosing—it begins with physicochemical properties baked into the scaffold . Solubility, lipophilicity (e.g., logP), and polarity govern whether molecules can cross membranes, dissolve in tissues, or survive circulation. Transporter affinity and solubility limits routinely sabotage otherwise strong ligands Effective PK optimization starts with realistic starting points Early property mapping accelerates the design–test–learn cycle Drug discovery is faster when chemistry starts aligned with biology, not fighting it. Absorption: Navigating Barriers to Entry Absorption remains one of the most context-dependent challenges in PK. While parenteral routes bypass absorption barriers, oral and topical delivery require navigating complex biological interfaces. Passive diffusion dominates for many small molecules, but protein binding, transporters, and tissue architecture  play decisive roles Dr. Kenakin highlights predictive in vitro permeation assays  that enable early iteration Absorption failures are rarely about route choice alone—they reflect mismatches between scaffold properties and biological surfaces Distribution: Beyond a Uniform Fluid Model The body is not a homogeneous container. It is a patchwork of semi-permeable compartments  that act as reservoirs, sinks, or barriers. Volume of distribution  provides a quantitative window into tissue partitioning Drugs that sequester into adipose or specialized tissues alter both efficacy and toxicity Dr. Kenakin presents cases where unexpected distribution profiles forced complete strategic pivots Plasma concentration alone is an incomplete proxy for exposure where it matters. Metabolism and Excretion: The Hepatic Engine Once in circulation, drugs encounter hepatic metabolism—primarily driven by cytochrome P450 enzymes —which governs clearance and duration of action. Metabolic conversion often inactivates compounds en route to renal excretion Species differences complicate translation from preclinical models Dr. Kenakin introduces mass-balance thinking and metabolic accounting  to proactively manage liabilities Clearance is not an endpoint—it is a design parameter. Predictive Assays: Assumptions and Opportunities High-throughput PK panels have transformed discovery, but they introduce new risks: overconfidence and black-box interpretation . In vitro–in vivo correlation depends on scaling assumptions and controls CYP inhibition, transporter assays, protein binding, and permeability all carry confounders Data quality hinges on experimental design and interpretive skepticism Tools inform decisions; they do not replace them. ADME as the Engine of Translation True PK mastery reveals its value at the point of translation. Even perfect receptor pharmacology fails if target-site exposure is insufficient or transient . Continuous PK integration —from scaffold design through population modeling— correlates with clinical success Scientists need to “think like a molecule” , tracing its path from administration to excretion Minor ADME adjustments —sometimes a single methyl group— can redefine clinical outcomes PK is the backbone of reproducible, actionable pharmacology. Why Terry’s Corner Terry’s Corner  delivers weekly pharmacology lectures from Dr. Terry Kenakin, monthly AMAs, and a growing on-demand library built around pharmacology's most important principles. Each session re-centers fundamentals, sharpens judgment, and equips scientists to identify problems before they become failures . Designed for pharmacologists, medicinal chemists, and discovery leaders who refuse to rely on assumptions. Forty years of expertise, applied to modern discovery. Explore the full library Or preview what’s inside: Read the latest articles 40 years of expertise at your fingertips : Explore the full library ➤

👉 Most biotech founders experience that external conversations consume more energy than they should . Investor calls take too long before reaching substance. Partner discussions sound positive but rarely lead to concrete next steps. Business development conversations feel inconsistent, even when the company and the science have not changed. 👉 The natural reaction is to improve communication. Founders refine their pitch, rewrite slides, and rehearse explanations. Yet better storytelling does not resolve the underlying tension . The conversations remain effortful, fragmented, and difficult to steer. 👉 This is not a communication problem. It is a biotech positioning problem. When biotech positioning is unclear, founders are forced to adapt their message in every interaction. They emphasize different elements depending on who is listening, which creates confusion instead of clarity. Over time, this constant adjustment drains confidence and momentum, even when the science is strong. ✅ Clear biotech positioning changes the nature of external conversations.   Instead of persuading, founders evaluate alignment. Instead of explaining everything, they provide context for decisions. The science does not become simpler, but the conversation becomes easier because its purpose becomes clear . Clear biotech positioning creates the conditions where scientific depth supports confident decisions and meaningful external conversations. The Symptoms of Unclear Biotech Positioning 👉 Most biotech founders feel that something is wrong in external conversations long before they can name the issue. The same company sounds different depending on the meeting , even when the science and the strategy have not changed. This inconsistency is not random. It is one of the clearest signals of unclear biotech positioning. 👉 When positioning is weak, similar conversations produce very different outcomes. External stakeholders leave meetings with different interpretations of what the company actually is , which slows momentum and increases friction. Over time, founders compensate by explaining more, not realizing that explanation is a symptom, not a solution. 👉 Unclear biotech positioning typically shows up in a few recurring ways: 1️⃣ Every external conversation drifts in a different direction , depending on who is asking the questions 2️⃣ Investor calls dive deep into science before relevance is established , making decisions harder, not easier 3️⃣ Partner discussions sound positive, but rarely convert into concrete next steps 4️⃣ Business development conversations focus on edge cases instead of the core value 5️⃣ The CEO and scientific leadership describe the company differently , even when aligned internally 👉 These symptoms are often misinterpreted as early-stage noise or communication gaps. In reality, they all point to the same underlying problem . Without a clear biotech positioning, there is nothing to anchor the conversation. Each external interaction becomes reactive, shaped more by incoming questions than by strategic intent. The most damaging effect is subtle. ✅ Founders start adapting their message in real time , trying to meet expectations instead of setting them. This creates the illusion of flexibility, but it actually erodes clarity. External stakeholders are left unsure how to evaluate the company, not because the science is complex, but because the positioning does not guide their decision-making . Until biotech positioning is clearly defined, these symptoms will persist. Improving slides or polishing the pitch may reduce surface-level friction, but the core problem remains untouched . Why Scientific Depth Does Not Create Market Clarity 👉 Biotech founders often assume that strong science will naturally lead to clear external conversations . The logic feels intuitive. If the data is solid and the mechanism is novel, clarity should follow. In reality, the opposite often happens. Scientific depth increases complexity. It introduces nuance, edge cases, and conditional statements. Without a clear biotech positioning, that complexity has nowhere to land . External stakeholders are forced to interpret relevance on their own, which slows understanding and weakens conviction. 👉 The core issue is that science answers how something works, but not why it matters now . Investors, partners, and business development teams are not evaluating scientific merit in isolation. They are evaluating decisions. Where does this fit? What does it replace? Why should attention shift? 👉 Scientific depth alone does not resolve these questions. When positioning is unclear, founders default to explanation. They walk through mechanisms, data sets, and future possibilities, hoping clarity will emerge along the way. This puts the burden of synthesis on the listener , who may not share the same context or priorities. The result is polite engagement without momentum. ✅ Clear biotech positioning reverses this dynamic. Instead of starting from depth, it starts from relevance. It defines the decision frame before the science is introduced. The science becomes evidence, not the story itself . External conversations become easier because the listener understands what they are being asked to evaluate. ✅ The solution is not to simplify the science. It is to decide what science stands for in the market . When that decision is made explicitly, depth stops being a liability. It becomes an asset that reinforces clarity rather than competing with it. Positioning creates clarity by aligning scientific depth with confident external conversations. How Clear Biotech Positioning Changes External Conversations 👉 When biotech positioning is clear, external conversations change in ways that founders immediately feel. The effort shifts away from persuasion and toward alignment , which reduces friction across every interaction outside the company. Instead of reacting to questions, founders guide the conversation. External stakeholders no longer need to guess what matters most. The positioning creates a shared frame before details enter the discussion . This is where clarity begins to compound. 👉 Clear biotech positioning consistently produces a few observable changes in external conversations. Conversations become shorter without becoming superficial , because relevance is established early Questions move from explanation to evaluation , signaling real engagement rather than polite curiosity Investors and partners respond with clearer next steps , even when the answer is no Founders stop adjusting their message mid-conversation , which increases confidence and coherence Alignment can be tested quickly , saving time and emotional energy on both sides 👉 These shifts do not happen because science improves. They happen because the decision context becomes explicit . External stakeholders understand what the company stands for, what problem it prioritizes, and why the conversation is happening now. This clarity removes a hidden burden from founders. 👉 They no longer carry the responsibility of making every detail meaningful in real time . The positioning does that work in advance. Science supports the conversation instead of driving it off course. ✅ The result is not smoother selling. It isa cleaner signal exchange . External conversations become easier because both sides know what is being evaluated. That ease is not accidental. It is the direct outcome of deliberate biotech positioning. What Biotech Positioning Strategy Really Means 👉 Many biotech founders misunderstand positioning because it is often confused with surface-level activities. Positioning is not branding, messaging, or slide design . Those are expressions. Positioning itself is a strategic decision that exists before any external communication begins. 👉 At its core, a biotech positioning strategy defines what your science stands for in the market . It clarifies which problem you are solving first, which audience you are prioritizing, and which decisions your company wants to influence. This clarity removes ambiguity not by simplifying reality, but by choosing a point of focus. 👉 Without this strategic choice, founders remain reactive. They respond to questions as they arise, adjusting emphasis depending on who is listening. This flexibility feels helpful, but it actually weakens trust , because external stakeholders cannot form a stable mental model of the company. Clear biotech positioning creates internal discipline. It establishes boundaries around what belongs in the story and what does not. Saying no becomes easier , not because options disappear, but because priorities are explicit. Science remains deep, but it is no longer directionless. 👉 The strategic value of positioning is revealed in conversation. External discussions stop being exercises in explanation and become tests of fit . Investors and partners can quickly assess relevance. Founders can quickly assess interest. Even rejection becomes useful, because it is based on clear criteria rather than confusion. ✅ A biotech positioning strategy does not make conversations easier by making claims louder. It makes them easier by making the meaning clearer . That clarity is what allows strong science to move forward without constant friction. Strategic Takeaway 👉 When external conversations feel difficult, most founders try to communicate better. That approach treats the symptom, not the cause . ✅ Clear biotech positioning is what makes conversations easier, not better wording . 👉 Once positioning is decided, conversations stop revolving around explanation and start revolving around fit. External stakeholders can decide faster, and founders waste less energy trying to adapt. ✅ If every conversation feels heavy, do not fix the pitch . Fix the positioning. Clarity inside the company is what creates ease outside of it. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

👉 Most founders look back at the end of the year and try to make sense of the results. They analyze numbers, milestones, missed goals, and unexpected outcomes. 👉 It feels logical to evaluate success where it is most visible . Yet that moment is usually the worst place to look for answers. What if the most important part of the year already passed long before those results showed up? 👉 What if the real leverage was never in the metrics but in the choices made when everything still felt open ? Early in the year, decisions feel small. Flexible. Reversible. But that is exactly why they matter more than we think. This is where strategic decision-making quietly shapes everything that follows , not through dramatic moves or bold announcements, but through subtle direction-setting that compounds over time. Most teams do not notice it happening. They only feel the consequences months later, when it is hard to change momentum. 👉 This article is about that hidden window. The moment when clarity is cheapest, alignment is easiest, and impact is highest . If you have ever wondered why effort does not always translate into results, the answer often lives much earlier than expected. The quality of your results is decided early. Strategic decision making sets direction long before outcomes become visible. Why Results Appear Too Late to Change the Outcome 👉 Most teams focus on results because results feel tangible. Revenue, milestones, completed experiments, and signed partnerships. They give the comforting sense that progress can be measured and managed . When something feels off, the instinct is to push harder and expect the numbers to follow. 👉 The issue is that results are never the moment when decisions are actually made . They are the visible consequences of choices that happened much earlier. By the time results show up, direction has already been set. Tradeoffs have already been accepted. 👉 What looks like a performance gap late in the year is often a strategic decision-making gap from the beginning . This creates a misleading sense of control. Teams believe they can correct course by adjusting execution. But execution only magnifies what already exists. It cannot compensate for unclear priorities or misaligned strategic choices . 👉 In biotech, where cycles are long and feedback is slow, this gap becomes even more pronounced. Founders who wait for results to diagnose problems are looking at the end of the story and hoping to rewrite the first chapters. At that point, flexibility has already faded . Budgets are locked. Teams are committed. Assumptions feel too costly to challenge. What once felt like optionality quietly turns into constraint. This is why late-year analysis often leads to frustration instead of clarity. ✅ The real leverage never lived in the results themselves , but in the earlier moments when strategic decision-making was still shaping the path forward. Where the Year Is Actually Decided If results are not the moment where control exists, then the real question becomes obvious. When does the year actually take shape ? For most founders, it happens quietly, early, and without much ceremony. This is the phase where choices feel lightweight, but their impact is anything but. Early in the year, teams make decisions that define how everything else unfolds. This is the true domain of strategic decision-making . Not because the answers are clear, but because uncertainty is still manageable and alignment is still achievable. These early decisions usually fall into a few recurring categories: 1️⃣ What does the team truly focus on? 👉 Every startup claims to have priorities. Few make real tradeoffs. Early strategic decision-making determines which initiatives receive attention and which are consciously deprioritized. Without this clarity, everything feels important, and nothing moves decisively. 2️⃣ How will it be defined internally? 👉 Milestones, progress signals, and success criteria are often assumed rather than agreed upon. Early decisions shape what the team optimizes for , even when no one explicitly states it. 3️⃣ What will not be solved this year? 👉 One of the most powerful early choices is deciding what to leave untouched. Strategic decision-making is as much about restraint as it is about ambition . Teams that skip this step carry an invisible scope that slowly drains focus. 4️⃣ How decisions will be made going forward? 👉 Founders rarely pause to define decision ownership and escalation paths. Yet early choices here determine speed, friction, and trust for the rest of the year. ✅ When these decisions are made deliberately, they create a sense of direction that feels almost effortless later on. When they are made implicitly, or not at all, teams spend the rest of the year reacting. ✅ Execution then becomes noisy, not because people are slow, but because the direction was never fully set . This is the moment where leverage is highest. Before momentum hardens. Before assumptions turn into dogma. ✅ Early strategic decision-making does not guarantee success, but it dramatically increases the odds of alignment and meaningful results . Timing shapes results. Early decisions set the direction long before outcomes appear. How Alignment Turns Decisions into Real Progress Strategic decisions only matter if they translate into action. This is where alignment becomes the invisible mechanism that turns intent into movement. 👉 Without alignment, even good strategic decision-making stays theoretical . With alignment, execution starts to feel lighter, faster, and more coherent. Alignment is not agreement on every detail. It is a shared understanding of direction. When early decisions are clear, teams spend less energy interpreting what matters and more energy moving forward. ✅ Clarity removes the need for constant recalibration . People stop guessing. Priorities stop shifting week to week. This is especially critical in science-driven organizations. Biotech teams operate across disciplines, timelines, and incentives. When strategic decision-making is vague, each function optimizes locally. Science pushes depth. Business pushes speed. Operations push stability. Alignment is what allows these forces to reinforce rather than cancel each other. 👉 The absence of alignment shows up in subtle but costly ways. Meetings multiply. Decisions slow down. Execution feels busy but not effective. Teams mistake motion for progress . Over time, this friction compounds and erodes confidence, even when the underlying strategy is sound. 👉 When early strategic decision-making creates alignment, something changes. Decisions no longer feel heavy. Tradeoffs feel intentional rather than painful. Execution becomes a reflection of shared direction, not constant negotiation. ✅ Results improve because they are finally pulling in the same direction . ✅ This is why alignment is a force multiplier. And it is built far earlier than most teams realize, at the moment when strategic decision-making still has room to shape behavior rather than react to it. How Founders Can Strengthen Strategic Decision Making Early Once founders recognize the role of early decisions and understand how alignment works, the next question becomes practical. 👉 How can strategic decision-making actually be improved when the year is just beginning? This is not about adding more meetings or creating heavier processes. It is about making a few critical choices explicit while flexibility still exists. Strong early decision-making starts with intention. 👉 Founders who take control of this phase do not try to solve everything. They focus on creating a clear decision environment that supports consistent execution later on. At this stage, a few simple actions make a disproportionate difference. 1️⃣ Clarify what truly matters now.  👉 Not everything deserves equal attention. Strategic decision-making improves immediately when priorities are stated clearly and revisited deliberately. 2️⃣ Make assumptions visible.  👉 Early alignment depends on shared assumptions. When they stay implicit, teams optimize in different directions without realizing it. 3️⃣ Decide how decisions will be revisited.  👉 Good strategic decision-making leaves room for learning. Founders who define when and how decisions can be challenged reduce fear and defensiveness later on. These steps do not eliminate uncertainty. They create a structure that allows uncertainty to be handled productively . Instead of reacting to pressure as it appears, teams operate from a shared foundation that makes course correction possible without chaos. ✅ When founders invest in strategic decision-making early, they are creating the conditions where better decisions become easier throughout the year. Strategic Takeaway ✅ Strong results are shaped much earlier through strategic decision-making , when direction is still flexible, and alignment is easy to build. ✅ Founders who focus on early decisions create clarity that lasts. Execution becomes smoother. Teams move faster with fewer corrections. The results follow because the groundwork was done at the right moment . ✅ A strong year is not something you fix later. It is something you design early, one deliberate decision at a time . Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

👉 In early-stage biotech , uncertainty is not an exception. It is the environment. The science evolves, assumptions break, and timelines shift quietly rather than dramatically. Most founders are prepared for this on a technical level. What they are less prepared for is how much this uncertainty tests the team. Early hiring decisions are usually made around skills, experience, and domain expertise. That feels logical. 👉 Complex biology seems to demand strong credentials.  But when the science starts to drift, teams often discover something uncomfortable. Some people keep moving. Others wait. Not because they lack intelligence or motivation, but because they were hired for clarity, not for uncertainty . 👉 In early-stage biotech hiring, the real risk is not weak science. It is building a team that cannot operate when answers are incomplete. ✅ This is where survival is decided. Early-stage biotech hiring is not about perfect resumes. It is about building a team that can operate when clarity is missing. Why Skill-Based Hiring Breaks Down in Early-Stage Biotech Most early-stage biotech teams hire with good intentions. The science is complex, the stakes are high, and mistakes feel expensive. So founders optimize for competence. 👉 Strong resumes feel like protection against uncertainty. This logic works in stable environments. It works when roles are defined, processes exist, and the path forward is mostly known. Early-stage biotech is none of those things. 👉 In early-stage biotech hiring, skills are selected based on an implicit promise. That the biology will behave well enough for expertise to compound. Those milestones will arrive in the expected order. That execution will follow the plan. When those conditions hold, skill-based hiring looks smart. When they do not, it starts to fail quietly. As the science shifts, highly skilled people often hesitate. They wait for clearer data. They ask for tighter definitions. They look for certainty before committing. 👉 This is not incompetence. It is a rational response trained by environments where clarity existed. The problem is that early-stage biotech rarely offers that clarity. Especially in discovery-driven programs, the work happens between answers. Progress depends on decisions made with incomplete information. Teams that rely only on skill depth struggle here because skills alone do not tell people how to act when the rules are missing. This gap becomes visible fast. Meetings slow down. Ownership becomes fuzzy. Decisions escalate upward. Founders feel the pressure to hold everything together. The team is talented, but momentum starts leaking. 👉 Early-stage biotech hiring fails at this point, not because the science is too hard, but because the hiring logic was built for a reality that does not yet exist . Skills are necessary. They are never sufficient. This is the moment where founders begin to realize that survival depends on something else. The Difference Between Competent and Useful in Early Stage Biotech As uncertainty increases, a subtle shift happens inside the team. The question is no longer who is the most qualified. It becomes who is actually useful when answers are missing . 👉 In early-stage biotech hiring, competence is easy to recognize. It shows up in credentials, past roles, and technical depth. Usefulness is harder to spot. It only becomes visible once the science stops behaving, and decisions still need to be made. This is where many teams get stuck. They are full of capable people, yet progress slows. The issue is not ability. It is behavior under uncertainty. 👉 Here is what separates competent people from useful ones in early-stage biotech environments. 1️⃣ Decision making without complete data: Useful people do not wait for perfect information. They assess what is available, understand the risk, and move forward. They know that waiting is also a decision. 2️⃣ Ownership without clear boundaries: When roles are still forming, useful team members step into gaps instead of protecting job descriptions. They act as if the problem belongs to them. 3️⃣ Momentum between milestones: Competent people perform well when goals are defined. Useful people create progress when milestones slip or dissolve entirely. 4️⃣ Emotional stability during scientific ambiguity: Early-stage biotech generates long periods of not knowing. Useful people remain constructive during these phases instead of becoming defensive or disengaged. 👉 None of these traits replaces skills. They determine whether skills can be applied at all.  In environments where the plan changes often, usefulness becomes the multiplier. This is why early-stage biotech hiring breaks when founders optimize only for what is visible at the interview stage. Competence shows up early. Usefulness reveals itself only under pressure. ✅ Recognizing this difference changes how founders evaluate talent. It also changes what questions matter when building the team. Built for growth means building a biotech team that can learn, adapt, and move forward together as the science evolves. What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize that survival traits are not abstract qualities. They show up in very concrete moments. Usually, when the science refuses to cooperate. In early-stage biotech hiring, these moments arrive quietly. A key experiment produces ambiguous results. A lead program slips without a clear explanation. The discovery phase stretches longer than planned. In teams working on complex biology like GPCR targets, this kind of drift is not unusual. What matters is how people respond to it. Some team members retreat into analysis. Others disengage emotionally. But a few keep the company moving forward even when certainty is missing. 👉 They reframe the problem, adjust priorities, and make decisions that preserve momentum without pretending to have all the answers. These are not heroic behaviors. They are practical ones. Survival traits express themselves as calm under ambiguity, a bias toward action, and the ability to separate progress from perfection. People with these traits do not fight uncertainty. They operate inside it. 👉 This is why early-stage biotech hiring needs a different lens. Skills determine what someone can do when conditions are stable. Survival traits determine whether anything gets done when they are not. Founders who recognize this early stop asking whether a candidate is impressive. They start asking whether that person can still be effective when the ground shifts under their feet. How Founders Can Hire for Survival Without Overengineering It 👉 Once founders recognize that survival traits matter, the next question is practical. How do you actually hire for this without turning the process into guesswork or psychology? The answer is not more complex interviews or longer job descriptions. In early-stage biotech hiring, what matters is where you focus your attention . Survival traits reveal themselves in how people talk about uncertainty, ownership, and unfinished work. Instead of testing for theoretical excellence, founders can shift toward observing real behavior. 👉 Here are a few practical signals that consistently matter in early-stage biotech environments. 1️⃣ How candidates describe moments without clear answers: Listen to how they talk about uncertainty. Do they freeze, escalate, or adapt? Useful people explain how they moved forward despite missing information. 2️⃣ How they react to shifting priorities: Ask about situations where plans changed midstream. Survival-oriented candidates show adjustment, not frustration. 3️⃣ How they define responsibility: Pay attention to whether ownership is framed narrowly or broadly. Early-stage biotech rewards people who take responsibility beyond their formal scope. 4️⃣ How they balance rigor and progress: Strong candidates understand scientific rigor. The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but they are reliable. They do not replace skills. They determine whether skills translate into momentum. When founders make this shift, hiring becomes less about finding the perfect profile and more about building a team that can function while reality is still forming. ✅ That is where early-stage biotech hiring stops being fragile and starts becoming resilient. Strategic Takeaway 👉 In early-stage biotech hiring , the goal is not to eliminate uncertainty. That is impossible. The goal is to build a team that can operate while uncertainty is present. 👉 Skills matter. Experience matters. But survival depends on how people behave when the science shifts and the plan no longer leads . Teams that endure are not the ones with the most impressive resumes. They are the ones where individuals can decide, adapt, and move forward without waiting for perfect clarity. For founders, this is not about fixing past hires. It is about making the next decision more intentional. ✅ Hiring for survival traits is how early-stage biotech teams stay functional long enough for the science to catch up. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

👉 Biotech startups rarely fail all at once. They usually fail while everyone is still working hard.   Experiments continue. Meetings happen. Progress is reported. Yet over time, alignment fades, and decisions start to feel disconnected. 👉 Many founders ask why biotech startups fail  not after a collapse, but when the company starts to feel harder to run without a clear reason . Nothing is obviously broken, but clarity is missing. Priorities blur. Execution slows. This is not a motivation problem. It is a structural one.  When complexity grows faster than strategy, biotech companies begin to fall apart quietly. 👉 This article examines why biotech startups fail when strategy is absent , and how that outcome can be changed. The difference between surviving and failing in biotech is rarely science. It is whether clarity exists when complexity grows. When complexity grows faster than clarity 👉 Early-stage biotech is complex by default. Science evolves in parallel with regulatory funding pressure and team growth.   Each of these dimensions introduces uncertainty. On their own, none of them is fatal. The problem begins when they expand faster than the company’s ability to make clear decisions. Most founders do not notice this shift immediately. Work continues. Experiments multiply. New ideas are added on top of existing ones. Complexity feels like progress.   👉 In reality, it often signals that priorities are no longer explicit. This is one of the earliest reasons why biotech startups fail . Not because the science stops working, but because the organization stops knowing what matters most right now . When everything feels important, nothing truly is. Without strategic filtering, teams accumulate parallel efforts. Scientists explore promising side questions. Leadership avoids saying no because every option feels valuable. Over time, focus dissolves. 👉 The company becomes busy instead of deliberate. At this stage, failure does not look like failure. It looks like motion. But motion without clarity slowly erodes confidence, execution, and trust.  Decisions become harder. Tradeoffs are postponed. The cost of complexity compounds quietly. 👉 The danger is not that biotech is hard. The danger is letting complexity grow without a structure that contains it.  When clarity does not scale with ambition, disorder fills the gap. The illusion of progress and the slow loss of direction One of the most dangerous phases in a biotech startup is when everything appears to be moving forward . Experiments are running. Data is being generated. Timelines are discussed with confidence. From the outside, progress looks real. 👉 Inside the company, however, direction often becomes unclear. Activity replaces alignment.  Teams execute tasks without a shared understanding of which decisions those tasks are meant to inform. Milestones are reached, but no meaningful choices follow from them. This is a central reason why biotech startups fail . Progress becomes performative rather than strategic. Work is measured by output instead of insight. The organization stays busy, but learning slows down. 👉 This pattern usually shows up in a very specific way: 1️⃣ Experiments are added faster than old ones are stopped 2️⃣ Milestones exist, but they do not unlock real decisions 3️⃣ Data accumulates without changing direction 4️⃣ Roadmaps grow longer instead of sharper 5️⃣ Everyone is working hard, yet priorities feel unstable Each item on its own looks reasonable. Together, they create drift. More experiments feel safer than fewer deliberate ones.  Additional data feels like risk reduction, even when it does not change the strategic picture. Over time, confidence erodes. Teams are no longer sure what success looks like. 👉 No single decision breaks the company, but the absence of decisive moments weakens it. The startup does not fail because it stops doing things. It fails because it stops knowing why it is doing them.  When progress is no longer tied to clear strategic questions, direction quietly dissolves. Clarity before chaos is what prevents biotech startups from slowly falling apart. Strategy as a system for making fewer better decisions The turning point for many biotech startups comes when strategy stops being a document and starts functioning as a decision system. ✅ The role of strategy is not to predict the future, but to reduce unnecessary complexity in the present. Teams that regain control do not suddenly become more confident about biology. They become clearer about what matters now and what does not.  Strategy creates a shared filter that connects science execution and business reality. ✅ At its core, this is what a functional strategy provides: 1️⃣ Clear priorities that limit parallel work 2️⃣ Explicit decision points tied to experiments and data 3️⃣ Agreed criteria for stopping as well as continuing 4️⃣ A common language for tradeoffs across science and leadership This is where the pattern of why biotech startups fail  begins to reverse. Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent. Data is no longer collected because it might be useful someday. ✅ It is generated to answer a specific question that unlocks a decision. Importantly, strategy does not slow teams down. It removes hidden friction.  When priorities are explicit, execution accelerates because teams no longer need constant alignment checks. Scientists understand why an experiment matters. Leadership understands what outcome would trigger a change in direction. ✅ The goal is not certainty. The goal is coherence.  When decisions follow a visible structure, complexity becomes manageable rather than overwhelming. Designing order before chaos becomes expensive What separates resilient biotech startups from those that slowly fall apart is not confidence or optimism. ✅ It is the presence of someone actively designing order while uncertainty is still manageable.   Order does not emerge naturally in biotech. It has to be built deliberately and revisited continuously. Founders who succeed understand that strategy is not a one-time exercise. It is a repeated act of clarification.   They pause regularly to ask which assumptions are still valid, which decisions are being avoided, and which activities no longer justify their cost in time, focus, or capital. This is where many teams escape the typical pattern of why biotech startups fail . Instead of letting chaos accumulate quietly, they surface it early. They make uncertainty explicit rather than hiding it behind optimism or additional experiments. ✅ They accept that clarity is a moving target and treat it as such. Designing order also changes how teams experience pressure. When priorities are visible and decisions are intentional, stress becomes directional rather than paralyzing. People know what they are optimizing for.   Tradeoffs feel purposeful instead of arbitrary. Most importantly, order creates trust. Scientists trust leadership because decisions are grounded in logic rather than mood. Leadership trusts execution because work is clearly tied to strategic intent. ✅ The company stops reacting and starts responding. Biotech does not become easy when an order is designed. It becomes survivable.  And in a field defined by uncertainty, that shift makes all the difference. Strategic Takeaway - Why biotech startups fail Biotech startups rarely fail because of a single mistake. They fail when complexity grows without structure and clarity.  Over time, this creates drift that no amount of effort can correct. ✅ Strategy is what holds a biotech company together under pressure.   It makes priorities explicit, decisions visible, and tradeoffs intentional. Without it, even strong science slowly loses direction. 👉 Understanding why biotech startups fail  is not about predicting collapse. It is about designing clarity early enough that chaos never takes over. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal work. What investors are really assessing is how clearly intellectual property supports the business being built . A strong IP position is not defined by volume. It is defined by alignment, control, and credibility . 👉 Many biotech fundraising efforts stall even with solid science and data. The issue is rarely the absence of intellectual property.  More often, the IP does not clearly map to the commercial story the company is telling. That disconnect creates uncertainty, and uncertainty is enough to stop momentum early. From an investor's perspective, biotech fundraising is a process of risk reduction. ✅ Intellectual property now acts as a proxy for how well a founding team understands and manages its core risks. ✅ When the IP story is coherent, trust builds quickly. When it is fragmented, even promising science struggles to move the round forward. Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech fundraising breaks before diligence even starts 👉 How does intellectual property become an early filter? Biotech fundraising rarely fails in the diligence phase itself. It fails earlier, often after the first or second meeting.  At that point, investors are not validating documents. They are pattern matching. 👉 What they are really asking is simple. Does this team understand how value will be protected if the science works? 👉 This is where intellectual property gaps start to matter. Not because something is legally wrong, but because the IP story does not answer investor questions clearly enough . Founders often present patents as proof of strength, while investors read them as indicators of risk management. 👉 An early red flag appears when intellectual property is treated as a static asset. Slides list filings and dates, but do not explain how those rights support the fundraising narrative . Investors then have to fill in the gaps themselves, and that rarely works in the founder's favor. In modern biotech fundraising, intellectual property functions as a shortcut. It signals whether the company has thought through scale, competition, and control.  When that signal is weak or confusing, investors slow down. When momentum slows, deals quietly disappear. 👉 Biotech fundraising does not stop because investors find a fatal flaw.   It stops because the IP creates unanswered questions that feel too expensive to explore further. The 3 IP gaps investors notice first 👉 How small misalignments quietly derail biotech fundraising? In early-stage biotech fundraising, investors do not analyze intellectual property in isolation. They evaluate how IP behaves as part of a larger system.  When that system shows cracks, confidence erodes quickly. The most common intellectual property gaps fall into three categories. None of them are legal mistake. All of them are strategic mismatches. 1️⃣ Intellectual property that is disconnected from the business being built This is the most frequent issue investors encounter. The science is strong, the patents exist, yet the IP does not clearly protect the company's commercial direction . Common signals include: 👉 Patents focused on one indication, while the business story targets another 👉 Claims that protect research use but not real-world commercialization 👉 Intellectual property that explains the science well, but not the value capture From an investor's perspective, this creates confusion rather than confidence.   If the IP does not map cleanly to how the company plans to generate returns, the fundraising narrative starts to feel unstable. The issue is not patent quality. It is the lack of alignment between intellectual property and business intent. 2️⃣ Ownership and control that feel unclear or constrained This gap appears most often in academic spinouts, but it is not limited to them. Even experienced founders underestimate how sensitive investors are to ownership details. Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights to future improvements or new filings 👉 Founders assume that investors cannot verify When ownership is ambiguous, investors struggle to understand who truly benefits if the company succeeds.   That uncertainty increases perceived risk, even if the underlying science is compelling. Importantly, this is rarely about bad decisions by founders. It is a system-level issue that becomes a fundraising issue when it is not clearly framed and explained. 3️⃣ No clear Freedom to Operate narrative Many biotech teams assume Freedom to Operate is a legal exercise that comes later. Investors see it differently. They are not asking for formal reports at the pitch stage. They are looking for evidence of strategic awareness. Red flags emerge when: 👉 Founders cannot articulate who might block market entry 👉 Competitive patents are acknowledged but not contextualized 👉 There is no discussion of workarounds or design choices The absence of a Freedom to Operate narrative signals unexamined risk.   Even if the risk is manageable, not addressing it makes the fundraising process harder. What matters most is not certainty. It is demonstrated thinking.  Investors want to see that the team understands the landscape it is entering. 👉 Why do these gaps matter so early? Individually, each of these issues might seem manageable. Together, they form a pattern. A pattern that suggests the company has not fully connected science, IP, and business into a coherent whole. In biotech fundraising, coherence builds trust. And trust is often what determines whether a conversation moves forward or quietly ends. From insight to funding, clarity turns analysis into investor confidence How IP Expectations Are Evolving Toward 2026 👉 What does this mean for biotech fundraising? Expectations around intellectual property in biotech fundraising are becoming more structured. This shift is not about stricter rules, but about earlier and clearer risk assessment . Investors want to understand sooner how intellectual property supports the business they are being asked to fund. What is changing is the focus. Less attention is placed on legal volume, and more on strategic coherence.  Intellectual property is increasingly evaluated together with development plans and commercial intent, not as a separate legal topic. Several patterns are already emerging: 👉 IP discussions happen earlier in fundraising conversations 👉 Investors look for alignment rather than legal perfection 👉 Founders are expected to show awareness of constraints and options ✅ Looking toward 2026, this trend is likely to continue. Biotech fundraising will favor teams that use intellectual property as a tool for clarity rather than protection alone.  When science, IP, and business reinforce each other, fundraising conversations move faster and with less friction. ✅ For founders, this creates an advantage. Clear intellectual property thinking reduces uncertainty and builds trust early.  In a selective capital environment, that clarity can be as valuable as new data. Strategic Takeaway - Founder Clarity 👉 Biotech fundraising rarely fails because intellectual property is missing. It fails when intellectual property does not clearly support the business being built.  This is not a legal issue, but a clarity issue. 👉 Founders who raise successfully treat intellectual property as part of their core narrative. They can explain what the IP protects, where its limits are, and how that fits the company's direction.  This makes investor decisions easier and faster. The key insight is simple. Fundraising rewards coherence.  When science, intellectual property, and business intent reinforce each other, trust builds early and momentum follows. ✅ For biotech founders, the takeaway is clear. Intellectual property is not a checkbox. It is a signal of how well you understand your own company. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence is the quiet force behind biotech momentum, the rhythm that turns intention into real progress. The Pattern: Your “Accidental Cadence” 👉 Every biotech has a cadence. The question is whether it’s intentional. I call the default version Accidental Cadence , the rhythm the company falls into when urgency, science, and founder bandwidth collide. 👉 What it usually looks like: Weekly priorities shift based on whoever raised the loudest concern. Investor updates happen when guilt spikes, not when alignment demands it. BD conversations move optimistically but without a structured readiness signal behind them. Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. The CEO oscillates between fire-fighting and “let’s step back and think,” depending on emotional energy. 👉 None of this looks dysfunctional from the outside. That’s the danger. 👉 From the inside, however, it creates a quiet drift: lots of activity, little compounding progress. Why This Is Dangerous A weak operating cadence doesn’t cause a crisis. It causes erosion . 👉 Investor confidence softens  because the story feels reactive. 👉 BD partners disengage  because timing and readiness seem inconsistent. 👉 Teams hedge their work  instead of committing to clear priorities. 👉 The CEO becomes the unofficial project manager , even if they believe they’re “empowering the team.” Many early-stage biotechs show the same pattern: strong scientific progress paired with an operating cadence built on reactivity, heroic sprints, long silences, last-minute preparation, and shifting assumptions about BD timing. In these situations, the science is rarely the real bottleneck. The cadence is. When teams adopt structured decision cycles, consistent narrative checkpoints, and predictable timeline discipline, the organization typically shifts from “busy but slightly lost” to “focused, aligned, and gaining traction.” Same people. Same science. A different cadence and a different trajectory. Strategy sets direction. Cadence creates movement. Progress is the result. The Three Components of an Effective Operating Cadence 👉 If you’re a biotech founder, your operating cadence is your real operating system. Here’s the framework I use when diagnosing and rebuilding it. 1️⃣ Cadence of Decisions: When You Decide, Not Just What You Decide Founders often obsess over the content of decisions. But what kills momentum is timing inconsistency . 👉 Without a defined decision cadence: Choices get deferred until you “have all the data.” Teams start planning around delays BD and investor messaging drifts Timelines become aspirational rather than operational ✅ What “good” looks like: Predictable decision points (monthly, biweekly, quarterly) aligned with science cycles, not emotions. Decisions are made once and communicated clearly. 2️⃣ Cadence of Communication: The Rhythm That Builds (or Erodes) Trust Communication is not a byproduct of progress; it is a mechanism  of progress. 👉 Weak cadence leads to: sporadic investor updates BD conversations that lack mutual timing expectations internal teams working with partial context narrative inconsistency across stakeholders ✅ What “good” looks like: A clean, repeatable communication rhythm: internal alignment weekly cross-functional integration biweekly investor check-ins monthly or per milestone BD narrative calibration monthly This doesn’t create overhead. It creates clarity . 3️⃣ Cadence of Execution: The Drumbeat That Keeps Timelines Honest Most biotechs believe they have execution problems. In reality, they have cadence problems  masquerading as execution issues. 👉 When your cadence is unstable: Timelines slip quietly Dependencies surface late Teams optimize for activity, not momentum Scientific surprises hit harder because the system has no buffer ✅ What “good” looks like: Short, predictable, cross-functional execution cycles that keep reality visible early: What moved? What didn’t? What must change? What deserves escalation? ✅ A stable cadence doesn’t eliminate surprise. It eliminates blindness . Strategic Takeaway Your biotech is already running on an operating cadence. The question is whether you  chose it. 👉 Founders don’t drift because they lack discipline. They drift because their cadence isn’t designed. The shift is simple: 👉 From reactivity → to rhythmic leadership 👉 From heroic effort → to structured momentum 👉 From “we hope next year is better” → to “our cadence ensures it will be.” ✅ If you want a stronger 2025, start by shaping the one thing that shapes everything else: your operating cadence. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments  are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Premium Sneak Peak:  Human Substance P–NK1R interactions observed by NMR; Endocrine Metabolic GPCRs 2026 and Biophysical Society Meeting previews; positive ACCESS data for Structure Therapeutics’ oral GLP-1 agonist aleniglipron, Principal Scientist—In Vitro Pharmacology. Terry’s Corner: GPCR Binding Affinity Experiments That Hold Up Orthosteric GPCR binding affinity experiments  sit at the core of drug discovery. They inform SAR, rank compounds, and influence which molecules move forward. Yet small design choices—often treated as technical details—quietly reshape the affinity you think you’re measuring. Tracer concentration, receptor density, equilibrium assumptions, and ligand kinetics all influence whether Ki and IC₅₀ values reflect molecular reality or experimental convenience. When these factors aren’t understood, binding data can appear precise while quietly misleading decision-making. In this Terry’s Corner lesson, Dr. Terry Kenakin reframes GPCR binding affinity experiments  as context-dependent measurements , not fixed molecular constants. By walking through saturation curves, displacement assays, stoichiometry pitfalls, and kinetic traps, the lesson equips scientists with a diagnostic lens: how to tell when affinity data are trustworthy—and when they are not. This week’s lesson helps you: Diagnose when equilibrium, tracer behavior, or stoichiometry distort affinity estimates , leading to false confidence in Ki values derived from GPCR binding affinity experiments. Interpret multi-phase binding curves correctly , recognizing G-protein coupling and kinetic effects rather than invoking multiple receptor populations. Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather than undermine—lead selection and development timelines. Already available in Terry’s Corner: 30 in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built for repeat use, not one-off viewing. More new courses arrive weekly in 2026, expanding coverage across GPCR pharmacology fundamentals. Premium Membership pricing increases in 2026, and the 67% Terry’s Corner discount is going away. Join before year-end to secure both. 👉   Join Terry's Corner Before Dec 31st, 2025 🎧 Dr. GPCR Podcast: When GPCR Tools Scale Even the most elegant tools only matter when they scale beyond a single lab. Academic innovation moves discovery forward only when assays are validated, distributed, and adopted across organizations. In Episode 3 of 3  of our series with Celtarys Research , leaders from academia and biotech unpack what effective collaboration really looks like when developing and scaling GPCR tools. Maria Majellaro, Johannes Broichhagen, and David Hodson discuss GLP-1 receptor probes, fluorescence-based assays, and why availability can matter as much as discovery itself. 🎧 Listen to Part 1 with Dr. Hudson 🎧 Catch up on Part 2 with Dr. Broichhagen You’ll hear: What it really takes to translate GPCR tools from academia into industry workflows How collaboration improves rigor, reproducibility, and screening impact Why scalable access amplifies the value of GPCR binding affinity experiments Listen to the final episode of the series ➤ Dr. GPCR Year in Review: Carrying Better Experiments Into 2026 As 2025 closes, the Dr. GPCR offers a clear signal of where the field is heading. This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. This growth reflects something deeper than metrics: a shared demand for clearer interpretation, stronger experimental design, and better decision-making across GPCR pharmacology. A quick rating on Spotify or Apple Podcasts — and a YouTube subscribe — helps us reach more scientists: Spotify: https://open.spotify.com/show/1KQHbC2qhkRIrdgBDtiQVF Apple Podcasts: https://podcasts.apple.com/us/podcast/dr-gpcr-podcast/id1514231064 YouTube: https://www.youtube.com/@DrGPCR Looking ahead to 2026: Live and on-demand University courses Co-creation pathways for academic contributors Launch of The Foundry , supporting strategy and CRO alignment In-person community moments, including GPCR Happy Hours Why Dr. GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who need signal, not noise . Each week, Premium delivers curated GPCR intelligence: expert-led lessons, classified industry updates, priority event alerts, and career-relevant opportunities—organized to support real decisions in discovery and development. Whether you’re refining GPCR binding affinity experiments , evaluating leads, or aligning teams around translational strategy, Premium provides context that helps you act with confidence. Beyond access, Premium sustains the nonprofit mission behind Dr. GPCR—supporting open resources while giving members deeper insight and earlier visibility. Already a Premium Member? 👉 Access this week’s full Premium Edition here ➤ Voice of the Community “It’s like being at a GPCR conference again—getting new ideas and hearing real scientific rigor.” The strongest discovery programs aren’t built on instrumentation alone—they’re built on interpretation that holds up. Happy holidays—and here’s to a 2026 of cleaner data and faster discovery. 👉 Become a Dr. GPCR Premium Member And Lock in The Current Rate➤ https://www.ecosystem.drgpcr.com/gpcr-university-pricing

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just a gradual slide into a world where the internal noise is high, but the external signal is near zero. 👉 The real issue isn’t the science. It's the isolation . Clear structure gives your science the visibility and consistency that traction is built on. The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes so dominated by experiments, data nuance, and scientific discourse that the organization loses strategic visibility, external traction, and narrative coherence. 👉 What it looks like in real life: Meetings end with explanations, not decisions BD calls “went great,” but nothing moves Timelines are built around assay availability, not strategic inflection points The phrase “after the next dataset…” becomes a company mantra Investor communication feels reactive and apologetic Key documents live in the CEO’s brain or slide decks that haven’t been touched in months 👉 From the inside, it feels like diligence. From the outside, it looks like ambiguity. Why Scientific Isolation Is Dangerous and Expensive This pattern rarely causes a single catastrophic failure. It causes a slow erosion of everything that matters. 1️⃣ External Trust Collapses Quietly Investors and potential partners don’t need more data; they need clarity. When the story isn’t evolving, they assume the company isn’t either. 2️⃣ BD Momentum Flatlines Pharma teams don’t chase raw science. They chase direction, intent, and timing. If you can’t articulate a trajectory, they categorize you as “interesting but unready.” 3️⃣ Internal Alignment Frays When “the science” drives everything, different teams start drifting at their own pace. This is how a 6-month slip appears without a single dramatic mistake. 4️⃣ Fundraising Windows Shrink Isolated science creates the illusion of runway control. In practice, founders overestimate how much time they have, usually by several months. The danger is subtle: 👉Scientific isolation feels busy, intelligent, respectable. But strategically, it’s suffocating. Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific isolation and back into momentum. The Three-Layer Anti-Isolation Framework Breaking scientific isolation isn’t about adding more process. It’s about restoring the connection  between science, strategy, and the outside world. 👉 Here’s a structure that consistently keeps companies out of isolation. 1️⃣ External Readiness (Are you visible and comprehensible to the outside world?) Most early biotechs think their problem is a lack of data. It’s usually a lack of narrative discipline. 👉 What this layer requires: A crisp BD trajectory that evolves every quarter A 1–2 page positioning document (“Why This Matters Now”) Predictable touchpoints with partners and investors, even without new results Good looks like: You can articulate your scientific rationale, commercial logic, and strategic sequence in five minutes, without slides . ✅ If you can’t do that, you’re isolated. 2️⃣ Internal Decision Systems (Do decisions only happen when new data appears?) In isolated companies, decisions are tethered to experimental data → no decisions. 👉 A functioning decision system introduces: clear thresholds default actions go/no-go moments ownership of decisions locked vs flexible timeline components Good looks like: The team knows what happens next, even when experiments slip . ✅ This alone removes much of the latent anxiety in early-stage teams. 3️⃣ Strategic Communication Cadence (Does everyone share the same story?) Most communication problems aren’t information gaps. They’re cadence gaps. 👉 A strong cadence is simple: Monthly CEO strategic alignment note Quarterly “state of the trajectory” session Bi-weekly refresh of BD and investor narratives A single, living source of truth for timelines and decisions It looks good: No one, from intern to CSO, board member, or pharma partner, gives a different story about what the company is doing and why. ✅ Coherence is momentum. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus. That’s why it’s so dangerous. 👉 The founder shift is this: from scientific immersion → strategic connection from data-dependency → decision-readiness from internal comfort → external relevance ✅ Your science is the engine. Your ability to connect it to investors, BD, the market, and your own team is the company. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric binding experiments remain a cornerstone of pharmacology, but they demand rigor. Terry Kenakin’s session examines not just how  binding works, but why  so many datasets mislead even seasoned scientists. In this session, you’ll gain: Why saturation and displacement assays fail when protein stoichiometry shifts How two-stage GPCR binding creates “high” and “low” affinity states What temporal kinetics quietly change about the affinity you think you measured Understanding Orthosteric Binding Foundations Orthosteric binding experiments rely on a measurable event: a tracer binds a receptor, and anything that displaces it alters that signal. But as Dr. Kenakin stresses, the apparent simplicity collapses once biological reality intrudes. Tracers bind not only to receptors but also to surfaces and unwanted proteins; non-specific binding must be corrected, not assumed. Running total and protected curves simultaneously is essential to reveal true receptor binding. Even the familiar saturation experiment hides traps. Linear-scale plots appear to plateau early, encouraging premature calls of B max. But plotting on a logarithmic axis exposes how far the system may actually be from true saturation. The midpoint and maximum—core parameters for downstream modeling—are only meaningful when the assay fully explores the system’s capacity. Unexpected outcomes typically trace back to a single issue: transferring assumptions from idealized models into messy GPCR systems. Take home message: interpret orthosteric binding data only after verifying that the biology behaved as expected. Displacement Curves and the Illusion of Potency Displacement assays measure affinity when no traceable analog exists. But potency in these curves is not intrinsic affinity—it shifts with tracer concentration. A displacer appears weaker at high tracer occupancy because more ligand must be displaced. In practice: The IC 50 you measure is a function of tracer levels. Changing tracer concentration moves the displacement curve. True affinity requires correcting for occupancy state. Earlier decades relied on Scatchard, Hanes, and other linear transforms to “clean” nonlinear data. Dr. Kenakin is unequivocal: do not use them. Modern computation handles raw nonlinear data precisely, whereas transforms distort error, compress dynamic range, and violate regression assumptions. When potency is mistaken for affinity, program decisions drift. Proper orthosteric binding design prevents those errors before they propagate into SAR narratives. Complex Two-Stage Biology Behind Orthosteric Binding GPCR pharmacology rarely follows the neat Langmuir adsorption isotherm. Proteins are not inert surfaces, and orthosteric binding reactions often continue beyond the first encounter. After a ligand binds, the receptor may transition further—often via G protein coupling. That second step stabilizes a higher-affinity configuration, explaining classical “high” and “low” affinity states. Mechanistically: Ligand binding (A + R → AR) is only step one. AR can become AR* or ARG, raising apparent affinity. The measured affinity becomes an operational composite. Removing coupling partners (e.g., GTPγS) collapses the system to a single low-affinity curve. This is not receptor heterogeneity—it is a collapsed two-stage system. Understanding these transitions is essential for interpreting orthosteric binding data accurately. Stoichiometry: The Quiet Driver of Curve Shape Two-stage systems expose how easily stoichiometry distorts outcomes. When G proteins are abundant, curves look clean because every receptor–ligand complex can couple. When receptor levels rise or G proteins become limiting, the system becomes stoichiometrically constrained. The high-affinity state is undersupported, creating biphasic curves. This frequently masquerades as: Two binding sites Multiple receptor subtypes Allosteric modulation But often the explanation is simpler: depletion of a required binding partner. Overexpression systems are particularly vulnerable. High receptor levels also deplete free tracer when tracer concentrations are low, breaking the assumption that added concentration equals free concentration. Across CRO-generated binding panels, this remains one of the most common sources of erroneous affinity estimates. Distinguishing Multiple Sites from Two-Stage Orthosteric Binding Genuine multiple-site binding has its own diagnostic signature. When a tracer binds two sites with different affinities, curve shape reflects the ratio of affinities and abundance. Small differences produce subtle curvature; large differences produce biphasic behavior. Clues that point to true multiple-site binding rather than two-stage GPCR biology: Disrupting G protein coupling does not  collapse the biphasic curve. Changing receptor expression or G protein levels does not  remove curve heterogeneity. Curve shifts track site properties, not system stoichiometry. Dr. Kenakin's message is practical: never assign “two sites” before ruling out two-stage orthosteric binding and stoichiometric imbalance. Experimental Conditions That Make or Break Orthosteric Binding Data Dr. Kenakin outlines a pragmatic checklist for producing reliable orthosteric binding measurements: Cell type and receptor expression:  Overexpression can distort stoichiometry and drive artifacts. Protein concentration:  Too much receptor depletes tracer and invalidates mass-action assumptions. Non-specific binding control:  Adsorption to surfaces changes free ligand concentration. Equilibration time:  Many assays stop before the system reaches equilibrium, especially with slow competitors. Clear curves are not evidence of equilibrium. Dr. Kenakin demonstrates how premature stopping mis-ranks compounds, particularly when tracer and displacer bind at different rates. Ensuring equilibrium is non-negotiable. Temporal Kinetics and the Hidden Bias in Affinity Kinetic imbalance is one of the most common—and least recognized—artifacts. If the tracer binds faster than the displacer, early time points exaggerate tracer occupancy and underestimate competitor potency. If the displacer binds faster, the opposite occurs. Many programs unknowingly compare compounds measured under different kinetic biases. You may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve shape → hints about missing equilibrium Real-time binding systems remove the guesswork. By observing the full onset and offset kinetics, scientists obtain affinity, kinetic rates, and equilibrium confirmation in one experiment—ideal for GPCR-focused discovery teams. Why Terry’s Corner Weekly pharmacology sessions with Dr. Terry Kenakin give scientists an uncommon advantage: the ability to interrogate foundational assumptions before they distort program decisions. Through deep-dive lectures, monthly AMAs, and a growing on-demand library, the Corner helps discovery teams refine binding strategy, troubleshoot complex GPCR systems, and understand when orthosteric binding data is lying—and why. Built for pharmacologists strengthening fundamentals, program teams navigating bottlenecks, and leaders who need credible guidance fast, the Corner brings clarity to the complexities shaping modern GPCR innovation. Those who invest now shape the breakthroughs that follow. This orthosteric binding lesson closes out the year—marking 30 courses released  and 3 live AMAs hosted  since launch. As we prepare for the next wave of content in 2026, Premium members receive 67% off Terry’s Corner throughout 2025 , unlocking full access to every session already available and all new weekly releases next year. As a member, you get: ✅ Full access to every course  — All 30 lessons released this year, plus new ones launching after the year-end break. ✅ AMA replays + priority Q&A  — Rewatch all 3 live AMAs and move your questions to the front of the line. ✅ Deep-dive learning paths  — Structured progression from foundational concepts to emerging and expert-level decision making. ✅ Member-only pricing  — Preferred rates across Terry’s Corner and the broader Ecosystem Premium. 40 years of expertise at your fingertips : Explore the full library ➤

Every scientist has stood in a crowded conference room rehearsing a question they’re too nervous to ask. The expert they admire is right there, but the fear of sounding unprepared wins. Yet one well-timed question can unlock clarity, accelerate a stalled project, or even spark a collaboration. In this episode, JB pulls the curtain back on the mindset and tactics he’s used for years—including the exact line that makes intimidating conversations surprisingly easy. It’s a masterclass in asking better questions in science, not as a skill you’re born with, but one you can intentionally build. Curiosity as the Engine Behind Asking Better Questions in Science JB’s story makes one thing clear: asking better questions in science starts long before the conference hallway. It starts by noticing what grabs your attention, what sparks those quiet “aha” moments during a lecture or when reading a paper, and what you can’t stop thinking about afterward. Throughout his training, he treated curiosity not as a trait but as a deliberate method. When an idea clicked, he paused, dissected it, and followed the thread. That discipline—paying attention to the internal spark—became the foundation of his scientific communication style and the steady confidence he brings into every discussion. Following curiosity is the first step toward asking better questions in science. When curiosity becomes intentional, questions become easier, sharper, and more useful. The One-Line Icebreaker That Makes Asking Better Questions in Science Easy At conferences, most early-career scientists freeze. JB short-circuits that anxiety with a single line he’s used for years: “Hi, I’m JB. I’m running into a problem and I know you work on something similar — can I pick your brain for one minute?” This opener works because it’s honest, specific, and respectful. You’re stating your purpose without hedging, signaling awareness of the other person’s expertise, and framing the conversation as short and attainable. And once the ice breaks? One minute becomes ten. Ten becomes an idea, a solution, or a collaborator. This is the practical side of asking better questions in science: not the wording, but the willingness to start. That first sentence is often the only barrier between you and the insight you need. Overcoming the Fear That Blocks Asking Better Questions in Science The biggest obstacle isn’t lack of knowledge—it’s fear. Fear of sounding inexperienced. Fear of asking something “basic”. Fear of wasting someone’s time. JB dismantles that fear with a refreshing truth: not knowing something isn’t a flaw—it’s common ground. Entire rooms full of scientists wonder the same things you do. Asking better questions in science requires accepting that uncertainty is part of the process, not a personal failing. When you articulate a question out loud, the assumptions become visible. The problem sharpens. The path forward emerges. Silence, by contrast, protects your ego but slows your research. As JB puts it, the cost of not asking is much higher than the cost of momentary discomfort. Why Asking Better Questions in Science Improves the Work Itself For JB, questions fuel the way he designs chemical probes, collaborates with biologists, and navigates technical barriers. His tools exist because he constantly asks: What limitation is chemistry solving here? What limitation is biology solving? What are we missing because we aren’t looking at the system correctly? This cross-functional back-and-forth is exactly how breakthroughs happen. In his collaboration with David Hodson, every major leap—from early ligand design to GPCR visualization tools—started with someone asking a question neither side could answer alone. Asking better questions in science isn’t a soft skill. It’s an R&D accelerant. It shortens feedback loops. It reveals flaws early. It stops wasted experiments. And it transforms collaborators into co-problem-solvers. Better questions lead to better data, faster decisions, and fewer wrong turns. Building a Scientific Career Through Asking Better Questions in Science Late in the conversation, JB offers advice that should be printed on the badge of every first-time conference attendee: Be curious. Ask questions. Engage with people regardless of their seniority. This mindset shapes careers far more than publications alone. Throughout his own journey—from organic chemistry to chemical biology to GPCR imaging—every pivotal step was rooted in conversations he initiated by asking better questions in science. Your next collaboration, job, or insight might already be within reach. It may just require walking across the room and asking one thoughtful question. The scientist who asks the best questions builds the strongest network—and the most resilient expertise. This conversation is part of a three episode series produced in collaboration with our partners at Celtarys Research . For more insight and nuance, listen to the full episode with JB.  🎧 Listen to the full episode https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/chemical-probes-for-gpcr-imaging-and-internalization If JB's story resonates 🎧 Listen to part 1 of this series with Dr. David Hodson

Some breakthroughs don’t start with a hypothesis. They start with a sentence that freezes the room. I can image the whole islet. Not a single cell, not a cropped region, not a patch of fluorescence — the entire pancreatic islet , 100–200 microns across, lighting up in real time. That moment didn’t just validate a probe. It opened a new window into GPCR imaging in native tissue, and reshaped what this collaboration between a chemist and a biologist could make possible. The Moment GPCR Imaging Became a Turning Point Before the islet lit up, the collaboration wasn’t even aimed at imaging. Johannes “JB” Broichhagen trained as a synthetic chemist — someone who trusted carbon–carbon bonds far more than live-cell behavior. Yet curiosity and chemistry pulled him into the world of GLP-1R, pancreatic β-cells, and the biological questions David Hodson had been exploring for years. The call from David — the glowing islet — created a pivot the team couldn’t ignore. A fluorescent peptide probe binding with clarity and specificity was exciting enough. Seeing that probe expose receptor distribution across an entire native islet changed what they believed was possible. This was more than data. It was ignition. A single successful GPCR imaging experiment can transform a project’s trajectory. From that moment, imaging wasn’t an add-on. It became the center of gravity. How a Chemical Design Sparked a GPCR Imaging Breakthrough The concept was elegant: antibodies weren’t delivering reliable GLP-1R visualization. A ligand-based peptide probe could, offer the consistency and surface selectivity GPCR imaging demands. One issue: JB had never made peptides Solution: collaborate. Working with a peptide specialist at the Max Planck Institute, the team moved quickly from concept to synthesis. What emerged was more than a ligand — it was a tool that enabled reproducible, stable, and high-contrast GPCR imaging across cells and tissue. Once the first images came in, the scientific questions multiplied: Could the probe support super-resolution GPCR imaging? Could they map receptor heterogeneity across the islet? Could they quantify plasma membrane vs. intracellular receptor pools? Could these tools scale to multiple GPCRs? The design didn't just work — it revealed. Interdisciplinary design isn’t optional in GPCR imaging. It’s the catalyst. The breakthrough didn’t happen because the chemistry was perfect. It happened because the chemistry and the biology met in the right way. The Human Reaction Behind a GPCR Imaging Milestone Scientists rarely talk about the emotional side of discovery — the instant where the experiment stops being data and starts being meaning. JB describes early experiences vividly: Seeing calcium waves flicker in cells. Realizing tissue is alive, unpredictable, and full of hidden structure. Feeling the urge to take phone pictures of super-resolution data and send them to collaborators because he couldn’t keep the excitement to himself. That same emotional imprint hit with the whole-islet image. It wasn’t just successful GPCR imaging — it was proof that receptors could be seen as they truly exist in native tissue, not simplified models. GPCR imaging doesn’t just visualize receptors. It gives scientists a way to feel the biology. This emotional spark carried the team through the next steps — validation, iteration, and expanding the scope of what these probes could do. Why Chemical Probes Shift the GPCR Imaging Landscape Chemical probes don’t replace antibodies outright — but they excel where antibodies struggle. For GPCR imaging, their strengths are practical and decisive: Consistency from batch to batch Long-term stability Compatibility with live cells and intact tissue Surface-receptor specificity A compact footprint that fits sub-10 nm resolution techniques These attributes enable experiments that previously required compromise. And the most striking validation came from in vivo GPCR imaging. Two-photon microscopy revealed a glowing islet in a living mouse — a moment JB calls the “Holy Grail” of chemical biology. Better GPCR imaging doesn’t just capture biology — it expands the biological questions the field can ask. The tools didn’t simply visualize receptors. They unlocked pharmacologically relevant insights that were previously inaccessible. The Collaboration Model That Makes GPCR Imaging Possible Behind every technical advance in this story sits something less tangible but equally decisive: a collaboration grounded in trust and fun. That’s how JB describes it — and it’s exactly why the work moved quickly. He learned tissue complexity from David; David picked up the quirks of acetonitrile. They exchanged instincts as much as data, and built a shared rhythm of problem-solving. Strong GPCR imaging tools come from strong interdisciplinary relationships. Good collaborations share protocols. Great collaborations share momentum. The trust between chemistry and biology drove the project forward faster than either discipline could have moved alone. Where GPCR Imaging Goes Next Once the breakthrough happened, the horizon widened dramatically. JB’s team now moves GPCR imaging toward: New fluorophores engineered for deep-tissue clarity Multi-color strategies for parallel receptor mapping Super-resolution imaging of receptor nanodomains AI-assisted probe design Multi-receptor visualization in complex tissue The dream is ambitious and increasingly feasible: A catalog where scientists choose a receptor, choose a color, and visualize biology exactly as it exists — in cells, in tissue, in living organisms. Not one receptor at a time. Not one color. Not one imaging depth. The islet lighting up wasn’t the pinnacle. It was the proof of concept. GPCR imaging is evolving from a specialized technique into a foundational method for receptor biology. And this breakthrough became one of the stepping-stones. This conversation is part of a three episode series produced in collaboration with our partners at Celtarys Research . If this behind-the-scenes story resonated, you’ll love the full conversation.  🎧 Listen to the full episode https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/chemical-probes-for-gpcr-imaging-and-internalization If JB's story resonates 🎧 Listen to part 1 of this series with Dr. David Hodson

The Gaps They Already See 👉 As a biotech founder, it’s easy to mistake volume for readiness . A solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like you’re ready for that pre-IND meeting. And yet, many founders walk out of their first FDA conversation with a quiet sense of confusion . 👉 No dramatic rejection. No loud red flags.Just a series of subtle but firm questions pointing to what’s missing . While you’re focused on showcasing what you’ve done, the FDA is already scanning for: What’s not there? Where does this break later? ✅ FDA approval is not a documentation checkpoint. It’s a strategic filter. Clarity, not complexity, is what makes approval possible, and biotech sustainable. The Illusion of Readiness 👉 Many biotech founders walk into a pre-IND meeting with quiet confidence . They believe their data package is strong, their models are validated, and they’re ready to move forward. But what looks solid internally often fails to signal true readiness from the FDA’s perspective . 👉 The real mistake is not scientific; it’s strategic . Founders often assume that regulatory readiness is just a matter of scientific progress . In reality, it’s about anticipating how the FDA will stress test your assumptions . 👉 While your team highlights compelling results , the FDA is already thinking differently. They are looking for what’s missing , not what’s impressive. Where’s your dose justification?   How consistent is your manufacturing?   What’s the rationale behind your patient stratification?   Is there a missing comparator?   How does this translate into a clear safety margin? These aren’t just documentation issues. They are signs of strategic incompleteness . Founders who prepare to present  often miss the deeper expectation: the FDA is not just listening, it is probing for structural weak points . And if your development plan was designed to persuade , not to withstand pressure , then you are not ready . 👉 Scientific strength does not guarantee regulatory clarity.  That is the illusion. What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. In reality, the FDA acts more like a systems-level risk assessor . They are not there to confirm what works; they are trained to identify what might break later . While founders try to demonstrate confidence, the FDA is systematically looking for structural weak points  across your development plan. And they are remarkably consistent in where they look. 👉 Here’s what the FDA is actually optimizing for, and where most early-stage teams fall short: 1️⃣ Predictable safety margins: Can your preclinical data meaningfully forecast patient safety in a first-in-human setting? 2️⃣ Dose selection logic: Is there a clear, mechanistic, and empirical rationale for how you plan to dose in trials? 3️⃣ Manufacturing consistency: Can you show that your process will be scalable, repeatable, and GMP-compliant from the start? 4️⃣ Comparative value: Have you positioned your therapeutic against the right standard or competitor, not just scientifically, but clinically? 5️⃣ Patient targeting rationale: Are you selecting the right patient subgroup with a clear justification for the benefit-risk balance? 6️⃣ Long-term viability signals: Does your data hint at durability, repeatability, or translatability, or are you building on single-use findings? Each of these areas points to the same thing: strategic foresight . The FDA is not asking for perfection; they are asking whether your plan shows signs of future collapse . 👉 When they spot a mismatch between your data and your development logic, it triggers doubt. And doubt slows down approval. ✅ The sooner you understand what they’re optimizing for, the faster you can align your strategy to de-risk not just your data, but your decisions . Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start with the science, generate data, reach milestones, and eventually think about approval. However, that sequence conceals a significant flaw; it treats FDA approval as the  final checkpoint , rather  than the initial filter . 👉 The most successful biotech teams flip this logic. They start by asking: What would FDA approval actually require from us, and what decisions need to reflect that now? This is the principle of strategic reverse engineering . 👉 It means designing your development path backwards , beginning with the criteria that the FDA uses to approve. Then you work upstream to define what your preclinical and early clinical data must demonstrate. That shift changes everything. Instead of collecting interesting data, you start collecting strategic evidence . Here’s how that mindset plays out in practice: You align trial endpoints with future label claims , not just scientific curiosity You design preclinical studies that support your dose justification , not just efficacy You plan manufacturing processes with scale-up and CMC documentation  in mind You assess safety signals based on their translatability to human risk mitigation This is not overengineering. It’s clarity. ✅ Reverse engineering from FDA approval is not about slowing down. It’s about building forward with fewer surprises, fewer iterations, and fewer expensive course corrections. FDA approval is not the end of your roadmap. It's the test of how well you built it. Building FDA-Ready Thinking into Your Strategy Regulatory success is not a function. It’s a mindset. The most resilient biotech startups are not the ones with the most experienced RA consultants; they are the ones where regulatory awareness is built into every key decision . This doesn’t mean turning your CEO into a regulatory affairs expert. It means shifting how your leadership team evaluates options. ✅ Every strategic decision, from indication selection to study design, should be filtered through the question: “What would this look like in an approval discussion?” 👉 FDA-ready thinking is not about documentation. It’s about decision architecture . Here’s how that shows up in strong biotech teams: 1️⃣ The CEO treats FDA clarity  as a strategic metric, not just a compliance task 2️⃣ The CSO aligns data generation with approval-relevant endpoints , not academic ones 3️⃣ The clinical lead evaluates protocols for regulatory traction , not just feasibility 4️⃣ The team knows that missing a question now means delaying approval later 👉 You don’t need a full regulatory department on day one. But you do need a framework for identifying and addressing regulatory gaps early . Because the truth is simple: 👉 The FDA already sees your weak points. If you can’t see them too, you’re not building strategy, you’re building surprises. Strategic Takeaway 👉 Biotech founders often view regulatory engagement as a milestone, a sign that things are moving forward. But approval is not a checkpoint. ✅ It’s a strategic mirror. It reflects every shortcut, every missed signal, every assumption you didn’t stress test. If you wait for the FDA to point out what’s missing, you’re already behind. Because by the time they do, your timelines will stretch, your budgets will strain, and your confidence will erode. The smart move is not to react faster. It’s to design smarter , from the very beginning. When you build with regulatory logic from day one, approval becomes a process of confirmation, not correction. ✅ That’s how real biotech strategy works. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.